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INTRODUCTION
The impact nonpracticing entities (NPEs), or “patent trolls,” have on
innovation may be the most important empirical question in patent law
today. So far, however, scholars have analyzed litigation brought by various
types of patent owners in a fragmented and indirect fashion. Some scholars
have studied only the most litigious or easily identifiable trolls.1 Such
studies miss as much as 85% of NPE-asserted patents.2 Others have focused
1 See John R. Allison et al., Patent Quality and Settlement Among Repeat Patent Litigants, 99
GEO. L.J. 677, 681-83 (2011) [hereinafter Allison, Patent Quality and Settlement] (comparing patents
asserted eight or more times with patents asserted just once); John R. Allison et al., Extreme Value
or Trolls on Top? The Characteristics of the Most-Litigated Patents, 158 U. PA. L. REV. 1, 5 (2009)
[hereinafter Allison, Extreme Value] (same); Michael Risch, Patent Troll Myths, 42 SETON HALL L.
REV. 457, 460 (2012) (studying only “the ten most litigious NPEs”); see also Sannu K. Shrestha,
Note, Trolls or Market-Makers? An Empirical Analysis of Nonpracticing Entities, 110 COLUM. L. REV.
114, 143 & n.160 (2010) (studying patent infringement cases filed by fifty-one NPEs identified in
the press).
2 Throughout this Article I refer to a dataset that I compiled using a random sample of 472
litigated patents that issued in 1993 and 1994. For a detailed discussion of my sample selection and
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exclusively on litigation filed during a handful of years in the last decade.3
These studies fail to account for the vast differences among patents that
happen to be litigated at the same time. It makes little sense, for example,
to compare the first and only litigation of a one-year-old medical-device
patent to the twentieth litigation of a nineteen-year-old software patent,
even if both proceed contemporaneously.
Perhaps not surprisingly, these narrow studies have produced results at
odds with one another. The empirical literature examining NPEs is, to put
it mildly, internally inconsistent. Some studies strongly suggest that NPEs
are every bit the tail that wags the dog. NPEs, for example, assert the lion’s
share of “most-litigated” patents4 and are especially dominant in high-tech
fields, where patents tend to be plentiful, cheap, and broad.5 Others report
the exact opposite. Trolls really don’t exist at all,6 exist but are exceedingly

data collection efforts, see infra Sections I.B–C. References to the information on patents and
cases in my dataset are cited throughout this Article to the Timing Dataset. Where the data relates
to the litigation of a particular patent, I include the patent number in the citation. The data is on
file with the author.
In the sample of cases gathered for this study, about 14% of NPE-asserted patents (twelve of
eighty-eight) were litigated in eight or more suits. About 7% (six of eighty-eight) were asserted by
the ten NPEs studied by Michael Risch. See Timing Dataset.
3 See Allison, Patent Quality and Settlement, supra note 1, at 682 (studying litigation brought
between 2000 and 2009); Allison, Extreme Value, supra note 1, at 5 (studying litigation brought between 2000 and 2007); Colleen V. Chien, Of Trolls, Davids, Goliaths, and Kings: Narratives and
Evidence in the Litigation of High-Tech Patents, 87 N.C. L. REV. 1571, 1593 (2009) (studying high-tech
cases filed between January 2000 and March 2008); Gwendolyn G. Ball & Jay P. Kesan, Transaction Costs and Trolls: Strategic Behavior by Individual Inventors, Small Firms and Entrepreneurs in
Patent Litigation 2 (Ill. Pub. Law & Legal Theory Papers Series, Research Papers Series No. 08-21,
2009), available at http://ssrn.com/abstract=1337166 (studying cases filed between 2000 and 2002).
4 Allison, Patent Quality and Settlement, supra note 1, at 692-93 figs.2 & 3 (reporting that
NPEs filed 63.5% of the patent cases involving a patent litigated eight or more times, but just 21%
of cases involving a patent litigated only once).
5 See id. at 695-96 & tbl.10 (reporting that over 74% of the most litigated patents cover
software-related inventions); Chien, supra note 3, at 1600, 1604 (reporting that NPEs filed 17% of
patent suits and were a party to 28% of patent claims in high-tech industries); Mark A. Lemley &
Carl Shapiro, Patent Holdup and Royalty Stacking, 85 TEX. L. REV. 1991, 2009 (2007) (estimating
that NPEs file 30-40% of patent suits in the computer and electronic industries).
6 See Robert P. Merges, The Trouble with Trolls: Innovation, Rent-Seeking, and Patent Law
Reform, 24 BERKELEY TECH. L.J. 1583, 1586 (2009) (“Some believe the troll label is a meaningless
epithet, applied only to a plaintiff in a patent lawsuit with whom one has a legal conflict.”);
Michael C. Smith, “Patent Pirates” Only Exist in Neverland, TEX. LAW., Oct. 11, 2004, available at
http://mcsmith.blogs.com/eastern_district_of_texas/files/patent_pirates_exist_only_in_neverland.pdf
(“[P]laintiffs in patent litigation are hardly pirates—they are simply investors who bought an asset
and seek a return on their money.”); Innovators Fear the Patent Trolls, TMCNET (May 7, 2006),
http://www.tmcnet.com/usubmit/2006/05/07/1639931.htm (“Patent trolls ‘don’t exist. Trolls are
imaginary creatures . . . . I think the whole issue is overblown.’” (quoting Carl Gulbrandsen,
Managing Dir., Wis. Alumni Research Found.)).

1312

University of Pennsylvania Law Review

[Vol. 161: 1309

rare,7 or exist in modest numbers but hold few of the traits attributed to
them by their detractors.8
This Article fills these gaps in the existing literature by studying a broad
cross-section of patents over the entire patent term. Rather than studying a
subset of patents linked by litigiousness or contemporaneous court filings, I
study all patent enforcement for a random sample of recently expired patents.
With this data, I can for the first time account for the relative timing of
lawsuits filed by practicing and nonpracticing entities. My findings are
dramatic: opposing views of NPEs in the literature ring true but at opposite
ends of the patent term. Product-producing companies predominantly
enforce their patents soon after they issue and complete their enforcement
activities well before their patents expire. NPEs, on the other hand, begin
asserting their patents relatively late in the patent term and frequently
continue to litigate their patents to expiration. Indeed, I find that the
average product-company patent has been shelved by its owner before the
average NPE patent has even been asserted.
The degree to which NPEs dominate the final few years of the patent
term is especially surprising. Though asserting just over 20% of all studied
patents, NPEs account for more than two-thirds of suits and over 80% of
infringement claims litigated in the final three years of the patent term.
Notably, NPEs’ domination of late-term litigation is almost completely
attributable to firms that do nothing more than hold patents. NPEs that
many do not consider trolls—universities9 and individual inventors10 in
particular—do not drive the results reported below.

7 Ball & Kesan, supra note 3, at 25 (concluding that the “number of patent licensing firms—
the most obvious candidate for the role of troll—active in cases filed . . . was quite modest”);
Nathan Myhrvold, Op-Ed., Inventors Have Rights, Too!, WALL ST. J., Mar. 30, 2006, at A14
(“Court records show that only 2% of all patent lawsuits are due to plaintiffs that have no ongoing
product business.”).
8 See Risch, supra note 1, at 474-91 (testing many of the common criticisms of NPEs and
concluding that “most of the criticism is based on a few, perhaps anecdotal, cases”); Shrestha, supra
note 1, at 148-49 (finding that “NPEs may be demanding high royalty fees not because of
opportunism, but because their patents are, in fact, more valuable” and that “NPE patents have
had considerable influence on subsequent patents and are also not trivial improvements in a
particular technology class”).
9 See Mark A. Lemley, Are Universities Patent Trolls?, 18 FORDHAM INTELL. PROP. MEDIA
& ENT. L.J. 611, 629 (2008) (arguing that universities are not patent trolls, at least in part because
they are “not engaged in hiding the ball, waiting until people have developed an industry and then
popping up and demanding a disproportionate share of royalties”); Randall R. Rader, Chief Judge,
U.S. Court of Appeals for the Fed. Circuit, Remarks at the Eastern District Bench Bar: The State
of Patent Litigation (Irving, Tex. Sept. 27, 2011) (“[T]he NPE designation sweeps in some
unintended ‘culprits’ like universities and research clinics and can also extend to almost every
corporation and business because they practice only a fraction of their patent portfolio.”). But see
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I also compare the relative litigiousness of product-producing companies
and NPEs, as well as differences in the subject matter and strength of their
infringement claims. In addition to my overall findings, I report how these
statistics change among patents litigated in the final years of the patent
term. I find that NPEs are especially litigious: they overwhelmingly assert
high-tech patents and lose at a relatively high rate when their infringement
claims are adjudicated on the merits. The same is true for patents litigated
late in the patent term: NPEs are more litigious, more high-tech focused,
and more likely to lose on the merits of their infringement claims. Interestingly, an outsized percentage of product producing–company patents litigated late in the term are high-tech related. These patents are asserted by a
unique group of companies, which sell a product and yet blur the line
between practicing entities and trolls.
My findings add to mounting evidence that the costs of NPE litigation
outweigh their benefits. In fact, they cast serious doubt on NPEs’ chief
alleged benefits: that paper patentees help create a market for innovation
and contribute to the dissemination of useful technology. Instead, NPEs
overwhelmingly wait to assert their rights until the underlying technology
is stale and unlikely to be of much use to accused infringers that independently developed the technology themselves years earlier.11 Overall, my
findings suggest that Congress should shorten the patent term by three
years or even longer.12 In these final years of patent protection, more than
80% of patent assertions are brought by patent-holding firms that have no
intention of commercializing a product. Much of the remaining litigation is
brought by product-producing companies asserting high-tech patents, often
with far less than ideal motivation. At the very least, Congress or the Patent
Merges, supra note 6, at 1611 (“[U]niversities, at least some of them, have crossed the line between
innovators and rent-seekers.” (footnote omitted)).
10 Chien, supra note 3, at 1587 (arguing that individual inventors should not be considered
NPEs).
11 See Christopher A. Cotropia & Mark A. Lemley, Copying in Patent Law, 87 N.C. L. REV.
1421, 1444-46 (2009) (finding that allegations of copying are rare in patent litigation, especially in
cases asserting high-tech patents); see also Markus Reitzig et al., On Sharks, Trolls, and Their Patent
Prey—Unrealistic Damage Awards and Firms’ Strategies of “Being Infringed,” 36 RES. POL’Y 134, 150
(2007) (developing a model of NPE behavior suggesting that the NPEs can “act most profitably as
sharks” when asserted patents are infringed inadvertently); John L. Turner, Patent Thickets,
Trolls and Unproductive Entrepreneurship 23 (Sept. 2012) (unpublished manuscript), available at
http://ssrn.com/abstract=1916798 (“[W]hen the frequency of inadvertent infringement is
smaller . . . [,] my model predicts that trolls will cause less of a change in rates of invention and
patenting and that their presence will harm welfare less.”).
12 For a discussion of study limitations that temper this recommendation, including a discussion of NPEs’ ability to simply file suit earlier in the event of a term reduction, see infra Section
III.C.
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and Trademark Office (PTO) should consider increasing the frequency and
magnitude of maintenance fee payments required in the latter half of the
patent term.
I. STUDY DESIGN
On the issue of patent reform, a civil war of sorts divides the technology
community.13 Battle lines are drawn largely between industries. Pharmaceutical companies, on one side, argue that strong patent rights are crucial to
continued innovation.14 High-tech firms, on the other, view the patent
system as more foe than friend.15 According to these firms, and many
scholars and patent attorneys, the patent system is too often a vehicle for
“patent trolls”—entities that assert patents they do not use and frequently
did not invent—to extract undeserved royalties from “true” innovators
working to build successful new high-tech products.16
How these opposing views of the patent system should be reconciled
turns in large part on questions concerning the utility of NPEs. Are NPEs
the pervasive litigation-cost “extortionists” their detractors make them out
to be?17 Or are they, as their defenders contend, small-time players that help

13 See, e.g., DAN L. BURK & MARK A. LEMLEY, THE PATENT CRISIS AND HOW THE
COURTS CAN SOLVE IT 4 (2009) (“Any doubts that the patent system is perceived by different
industries in fundamentally different ways were dispelled during the course of congressional
debates over patent reform in the four years beginning in 2005. The reform process ground to a
halt because different industries couldn’t agree on a single principle of reform.”); Merges, supra
note 6, at 1608-09 (“[R]ecent battles over patent reform in Congress show that there is a major
divergence between the interests of the biomedical industries . . . and information technology
companies . . . .”).
14 See BURK & LEMLEY, supra note 13, at 4 (“In the pharmaceutical industry, there seems to
be a strong consensus . . . that patents are critical to innovation.”).
15 See id. (“[T]he information technology industries . . . almost invariably see the patent
system as a cost rather than a benefit to innovation.”).
16 Patent “trolls” are so named because their behavior bears resemblance to mythological
trolls who emerge without warning from beneath bridges to demand a toll from all who would
pass. See Gerard N. Magliocca, Blackberries and Barnyards: Patent Trolls and the Perils of Innovation,
82 NOTRE DAME L. REV. 1809, 1814 (2007) (“The ensuing litigation comes as a surprise to a
defendant, which is why these suits are analogized to mythical trolls that hid under bridges and
leapt out to demand a ransom from travelers.”).
17 Timothy J. Haller & Sally Wiggins, The Patent Troll Myth, INTELL. ASSET MGMT.,
http://www.buildingipvalue.com/06US_Can/113_116.htm (last visited Mar. 15, 2013); see Magliocca,
supra note 16, at 1816 (“[Patent trolls] acquire an invention and then refuse to do anything until the
technology becomes an industry standard. This behavior is akin to setting a deliberate trap and is
not permitted elsewhere in the law.”); Merges, supra note 6, at 1600-02 (comparing the patent troll
business model to blackmail); Ted Sichelman, Commercializing Patents, 62 STAN. L. REV. 341, 368
(2010) (noting that NPEs “tend to exploit litigation and licensing market defects to extract
unwarranted rents from commercializers”); see also Rader, supra note 9, at 8 (“[E]xpenses can force
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disseminate useful technology,18 create markets for inventions,19 and
provide capital for inventors?20
A. Hypotheses
Unfortunately, the existing literature has done little to settle the debate.
One reason is that, even after several studies on the topic, commentators
cannot agree on the percentage of patent enforcement attributable to NPEs.
Results have been all over the map. NPEs, or some “trollish” subset thereof,
account for 2%,21 4%,22 22%,23 or 27%24 of patent litigation depending on
whom you ask. Though diverse, these relatively modest estimates have led
at least one scholar to declare that “the uniform findings indicate that NPEs
file only a small fraction of all patent infringement suits.”25 Other clues,
however, suggest that NPEs have anything but a modest effect on the
accused infringers to acquiesce to non-meritorious claims. This only serves as an unhealthy tax on
innovation and open competition.”).
18 See Brian D. Kacedon et al., Patent Trolls: A Stereotype Causes a Backlash Against Patents and
Licensing, FINNEGAN (Dec. 2006), http://www.finnegan.com/resources/articles/articlesdetail.aspx?
news=c49b5d62-61bf-4d90-99ad-30d4d6e9da23 (noting that the patent licensing community
“performs a central role in helping commercial entities obtain the rights to use valuable technologies that produce new and beneficial products”).
19 See James F. McDonough III, Comment, The Myth of the Patent Troll: An Alternative View
of the Function of Patent Dealers in an Idea Economy, 56 EMORY L.J. 189, 211 (2006) (“[Patent trolls]
make the patent market more efficient through buying and licensing patents. Patent dealers create
a credible threat of litigation, which encourages exchange, makes patents more liquid, and
facilitates market clearing through price equalization.”).
20 See, e.g., John E. Dubiansky, An Analysis for the Valuation of Venture Capital-Funded Startup
Firm Patents, 12 B.U. J. SCI. & TECH. L. 170, 171-72 (2006) (noting that venture capital firms have
begun to “assess and remarket the intellectual property of failed startup firms”); Ronald J. Mann,
Do Patents Facilitate Financing in the Software Industry?, 83 TEX. L. REV. 961, 1024 (2005) (“[T]rolls
are serving a function as intermediaries that specialize in litigation to exploit the value of patents
that cannot be exploited effectively by those that have originally obtained them.”).
21 Myhrvold, supra note 7.
22 Ball & Kesan, supra note 3, at 15 (finding that “3% of plaintiffs, who were active in 4% of
the cases, were licensing firms”).
23 Compare Patent Cases by United States District Court, LEX MACHINA ( Jan. 15, 2013) (on
file with author) [hereinafter LEX MACHINA] (reporting that 2541 patent cases were filed in U.S.
district courts in 2008, 2521 in 2009, and 2724 in 2010), with Litigations Over Time, PATENT
FREEDOM, https://www.patentfreedom.com/about-npes/litigations (last updated Jan. 18, 2012)
(showing that there were 559 NPE-filed suits in 2008, 546 in 2009, and 623 in 2010).
24 See Colleen V. Chien, Predicting Patent Litigation, 90 TEX. L. REV. 283, 314 (finding in a
sample of litigated patents issued in 1990 that 27% were asserted by either a “patent assertion
entity” or an individual); Sara Jeruss et al., The America Invents Act 500: Effects of Patent Monetization Entities on U.S. Litigation, 11 DUKE L. & TECH. REV. 357, 375-78 (finding, in a study of 100
patent suits filed each year from 2007 to 2011, that the percentage attributable to NPEs was
roughly 22% in 2007, 27% in 2008, 33% in 2009, 30% in 2010, and 40% in 2011).
25 Risch, supra note 1, at 466.
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patent system. One study found that NPEs owned more than 60% of
patents litigated eight times or more,26 and multiple studies have found that
NPEs file as much as 40% of suits asserting high-tech patents.27
What accounts for these seemingly inconsistent results? This Article
argues that existing studies of NPE litigation are incomplete because they
fail to take into account differences in the relative ages of patents asserted
by practicing and nonpracticing entities. It further suggests that all previous
empirical studies underestimate NPEs’ true impact because they fail to
compare NPE patents with other patents of the same age.
To date, no empirical studies have accounted for time in examining
patent litigation by NPEs.28 This omission is surprising because there is
good reason to believe that product-producing companies and NPEs assert
their patents on very different timelines. If, as many suggest, productproducing companies value their patents for exclusionary power,29 these
companies should file suit (if at all) soon after their patents issue to fend off
competitors that are developing or introducing similar products.30 In
addition, because products generally have short lifecycles relative to the
patent term31 and next generation products may be protected by newer
patents, practicing patentees should generally cease litigating a patent well

26
27

See Allison, Patent Quality and Settlement, supra note 1, at 690, 692.
See Chien, supra note 3, at 1600, 1604 (reporting that NPEs file 17% of patent suits and are
a party to 28% of patent claims in hardware and software industries); Lemley & Shapiro, supra
note 5, at 2009 (estimating that NPEs file 30-40% of patent suits involving computer and
electronic technology).
28 For example, Michael Risch found that highly litigious NPEs asserted their patents an
average of 8.3 years after issue, but he did not compare this delay with data on when productproducing companies do the same. Risch, supra note 1, at 490.
29 See, e.g., Daniel A. Crane, Intellectual Liability, 88 TEX. L. REV. 253, 286 (2009) (noting
that NPEs and product-producing companies “have asymmetrical incentives, since trolls are only
interested in exacting payments”).
30 Product-producing companies are also discouraged from delaying patent enforcement until
the patented technology matures by the risk that doing so will give their competitors time to
amass their own arsenal of patents, which they could use to file a successful counterclaim. See, e.g.,
Tom Ewing, Indirect Exploitation of Intellectual Property Rights by Corporations and Investors: IP
Privateering and Modern Letters of Marque and Reprisal, 4 HASTINGS SCI. & TECH. L.J. 1, 35 (2012)
(“Each company views its patent armamentarium as an instrument of mutually assured destruction, e.g., if one company sues another for patent infringement, then retaliation is guaranteed.”).
Because NPEs do not sell products that could be the subject of a counterclaim, they do not face
this risk when filing suit. See, e.g., John R. Allison et al., Patent Litigation and the Internet, STAN.
TECH. L. REV., no. 3, 2012, at 5, http://stlr.stanford.edu/pdf/allison-patent-litigation.pdf (“[NPEs]
do not make or sell products and thus are not vulnerable to patent infringement counterclaims, as
are product companies that sue for infringement. NPEs consequently may be less reluctant to sue.”).
31 In the computer industry, for example, products become twice as powerful about every
two years. See infra note 114 and accompanying text (describing Moore’s law).
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before it expires and move on to litigating newer patents covering newer
products.
By contrast, there is good reason to believe that NPEs overwhelmingly
litigate their patents late in the patent term. For one, many NPEs do not
file their own patent applications, but instead purchase patents on the
secondary market (often from failed companies32) for the purposes of
litigation.33 Naturally, it takes time for such patents to reach NPEs.34
Further, because NPEs primarily value patents for their usefulness in
extracting royalties and damages from product-producing companies,35
these patentees should generally wait to file suit until a lucrative industry
has developed and continue to file suits as long as deep-pocketed targets
remain.36
If these characterizations are rooted in fact rather than anecdote, it
makes little sense to base patent policy on calculations of the bare percentage of NPE suits among those brought during some year or group of years.
Product-producing companies are far and away the chief players in the
patent system and such studies will always reflect this fact.37 What these
studies cannot reflect, however, is whether NPEs begin to have a disproportionate effect at some point during the patent term and how such a finding
would color NPEs’ (and their defenders’) claims that they are beneficial
market makers and disseminators of technology.
B. Compiling a Database
To test these hypotheses, I set out to collect data on all litigation asserting a sample of recently expired patents. Using Westlaw and PACER,38 I
32 See Risch, supra note 1, at 489 (finding in a study of patents acquired by NPEs that more
than 14% of the original patent-holder companies were no longer operating and suggesting that
another 13% may have been in financial distress).
33 See, e.g., Crane, supra note 29, at 286 (“Patent trolls are firms that aggregate patents for
technology that they usually did not themselves create and do not themselves use, but for which
they seek to exact royalty payments from commercial users.”).
34 See infra notes 100-01 and accompanying text.
35 See supra note 29.
36 See Mann, supra note 20, at 1027 (noting the “especially damaging” strategy of “waiting
after a patent has been issued while an industry advances using the covered technology and then
suing widely for infringement only after the industry has become locked into the technology
through independent innovation and development”); Merges, supra note 6, at 1590-91 (“The
patent troll strategy is to take advantage of ‘lock-in’ that occurs as a result of [sunk cost] investments. Typically, the troll waits until a technology is fully entrenched before scouting around for
patents to acquire or asserting patents it holds.” (footnote omitted)).
37 See infra Figure 1.
38 See PACER, http://www.pacer.gov/ (last visited Mar. 15, 2013) (cataloguing case and
docket information from federal litigations).
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located every litigated39 patent40 that issued with a patent number falling
between 5,210,000 and 5,309,999. These patents issued between May 11,
1993, and May 10, 1994 (“the study period”).41
As shown in Table 1, I identified 1180 patents issued during the study
period42 that were litigated in a district court (including in U.S. territories)
or the Court of Federal Claims, or at the International Trade Commission
(ITC).43 In the ninety district courts located in the fifty states and the

39 Here and throughout, by “litigated” I mean asserted in an action raising a claim for infringement (or for a declaration of noninfringement or invalidity) of the studied patent, as
opposed to merely involved in litigation concerning ownership, inventorship, antitrust, contract,
trademark, copyright, or other patent claims. For an additional discussion of the kinds of cases
that were excluded from the study because they were not patent infringement cases, see infra
Section I.C.
40 Here and throughout, I use “patent” to refer exclusively to “utility” patents. This study
does not include design patents or plant patents, both of which are protected by separate statutory
schemes. See 35 U.S.C. §§ 171–173 (2006) (covering design patents) (amended 2012); id. §§ 161–
164 (covering plant patents).
41 Under the law in effect at the time these patents issued, each would have expired between
May 11, 2010, and May 10, 2011. See 35 U.S.C. § 154 (1988) (setting the patent term at seventeen
years from the date of issue). Legislation passed in December 1994 modifying the patent term for
patents then-in-force to the longer of seventeen years from issue or twenty years from filing.
Uruguay Round Agreements Act, Pub. L. No. 103-465, sec. 532, § 154(c)(1), 108 Stat. 4809, 498485 (1994) (codified as amended at 35 U.S.C. § 154(c)(1) (2006)). Because an application spends on
average close to three years at the PTO, these calculations generally provide a similar term of
protection. See John R. Allison & Mark A. Lemley, The Growing Complexity of the United States
Patent System, 82 B.U. L. REV. 77, 98 (2002) (finding that patents issued between 1996 and 1998
spent an average of 2.8 years in prosecution). Many patents, however, receive a modest extension
under the new law. See Mark A. Lemley, An Empirical Study of the Twenty-Year Patent Term, 22
AIPLA Q.J. 369, 385 (1994) (finding that, on average, the new rule for patent terms extended
patentees’ rights by 253 days).
42 The earliest patent issued on May 11, 1993. U.S. Patent No. 5,210,272 (filed Aug. 14, 1991).
The latest issued on May 10, 1994. U.S. Patent No. 5,309,861 (filed Aug. 5, 1992). The rate of
assertion during the study period (1.2%) is consistent with prior estimates of litigated patents. See
Mark A. Lemley, Essay, Rational Ignorance at the Patent Office, 95 NW. U. L. REV. 1495, 1501 (2001)
(“[A]t most only about two percent of all patents are ever litigated . . . .”).
43 Patent suits fall within the exclusive subject matter jurisdiction of federal courts, 28
U.S.C. § 1338(a), and may generally be brought in any United States district court which has
personal jurisdiction over the defendant, see Int’l Shoe Co. v. Washington, 326 U.S. 310, 316
(1945) (“[D]ue process requires . . . that in order to subject a defendant to a judgment in
personam, if he be not present within the territory of the forum, he have certain minimum contacts
with it . . . .”), and where venue is proper, see 28 U.S.C. § 1400(b) (permitting a suit for patent
infringement in any judicial district in which “the defendant resides” or “the defendant has
committed acts of infringement and has a regular and established place of business”). However,
patent claims against the United States must be brought in the Court of Federal Claims. 28
U.S.C. § 1498(a). Another exception is that the ITC has jurisdiction to investigate and exclude
imported goods that infringe a United States patent from entry into the country. 19 U.S.C.
§ 1337(a)(1)(B)(i), (c), (d). ITC orders barring the entry of infringing goods may be appealed to
the Court of International Trade. 19 U.S.C. § 1514(a). The Court of Appeals for the Federal
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District of Columbia, court clerks’ offices report basic information on patent
suits to the PTO, and searchable copies of these reports are available via
Westlaw’s Derwent LitAlert database.44 From these reports I identified 1159
patents.45 The LitAlert database, however, does not include records for
cases filed in the District Court of Puerto Rico and the three territorial
district courts.46 To locate all patents asserted solely in these courts, I
searched PACER docket reports and pleadings (where available47) for all
patent cases brought in each court during or after 1993 and cross-referenced
these results with all relevant patent numbers cited in opinions or orders
issued by these courts over the same period. From these records I found
another two unique patent numbers and two duplicates.48 Similarly, to
locate all patents asserted solely against the United States, I searched
PACER docket reports and pleadings for all patent cases brought in the
Court of Federal Claims during or after 1993 and cross-referenced these
results with opinions or orders issued by the court. This search identified
another seven unique patent numbers and one duplicate.49 Finally, to locate

Circuit holds appellate jurisdiction over the Court of Federal Claims, the Court of International
Trade, and all patent-related cases brought in district courts. 28 U.S.C. § 1295(a)(1), (3), (5).
44 Searching the LitAlert database confirms that all ninety districts located in the fifty states
and the District of Columbia submitted litigation reports to the PTO throughout the 1990s and
2000s. Thus, any missing patents should be attributable to idiosyncratic oversight rather than
systematic failure of any particular district to file reports with the PTO.
45 Patents from this timeframe were asserted in seventy-four of the ninety districts. See Timing Dataset. Based on patent filing data from Lex Machina, these seventy-four districts account for
over 98% of patent suits filed since 2000. See LEX MACHINA, supra note 23. And the top forty-six
of those districts, ranked by number of patent filings since 2000, are represented in the dataset I
analyze. Compare id., with Timing Dataset.
46 These three territorial courts are the District Court for the Northern Mariana Islands, the
District Court of Guam, and the District Court of the Virgin Islands. That these courts are
excluded is not surprising given that the District Court of Puerto Rico and the three territorial
districts collectively receive about one patent case per year. See LEX MACHINA, supra note 23
(reporting just fourteen patent suits filed in these four districts between 2000 and 2010). Virtually
all of these cases were filed in the District of Puerto Rico. See id.
47 Starting around the year 2000 and gradually increasing thereafter on a district-by-district
basis, federal courts have published filings and orders online in PDF format. Prior to electronic
filing, docket entries were described only briefly on docket reports. Thus, despite personally handsearching patent dockets in these districts, my dataset is potentially underinclusive for the District
Court of Puerto Rico, the territorial district courts, and the Court of Federal Claims. See Allison,
Patent Quality and Settlement, supra note 1, at 682 n.22 (describing the limitations in data collected
from PACER by the Stanford IP Litigation Clearinghouse). Nonetheless, collection in this
manner gives “the best, most representative data set available.” Id.
48 I identified a total of four patents issued during the study period that were asserted in a
territorial district court, but two were also asserted in a district court.
49 I identified a total of eight patents issued during the study period that were asserted in the
Court of Federal Claims, but one was also asserted in a district court.
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patents asserted only at the ITC,50 I searched Westlaw’s database of ITC
filings and cross-referenced these results with all relevant patent numbers
cited in opinions or orders issued by the United States Court of International Trade in or after 1993.51 Here, I found another twelve unique
patent numbers and twenty-two duplicates.
Table 1: Database Composition by Venue52
Venue

Total
Patents

Unique

U.S. Dist. Cts.

1159

--

U.S. Territorial Cts.

4

2

Ct. of Fed. Claims

8

7

ITC/Ct. of Int’l
Trade

34

12

Database Source
Westlaw: LITALERT
PACER; Westlaw: DCTGU,
DCTMP, DCTPR, DCTVI
PACER; Westlaw: FEDCL
Westlaw: USITC-FILINGS, FINTCIT

C. Sampling and Data Collection
From these 1180 patents, I randomly selected a sample of 472 (exactly
two-fifths) to investigate in depth. From this smaller sample, I excluded
fifty-one patents because they were never asserted against an alleged patent
infringer. Of these fifty-one, fourteen patents were involved solely in
litigation brought to resolve a dispute between putative owners or inventors.
Thirteen more were involved in patent false-marking cases brought after
the patents’ expiration.53 Another eighteen were not litigated, but only cited
50 Technically, the ITC’s jurisdiction is in rem, so the suit is brought against the allegedly
infringing goods themselves. See, e.g., Sealed Air Corp. v. U.S. Int’l Trade Comm’n, 645 F.2d
976, 985-86 (C.C.P.A. 1981) (noting that an ITC order to exclude products from entry into the
United States operates “against goods, not parties”).
51 Westlaw’s coverage of ITC filings dates back to December 1994. See Scope USITCFILINGS, WESTLAW CLASSIC, https://web2.westlaw.com/scope/default.aspx?db=USITC-FILINGS
&RP=/scope/default.wl&RS=WLW12.10&VR=2.0&SV=Split&FN=_top&MT=208&MST= (last
visited Mar. 15, 2013). Thus, this dataset is underinclusive to the extent that patents issued during
the study period were asserted at the ITC within twelve to eighteen months of their issue.
52 See supra notes 38-51 and accompanying text.
53 In the past, it was unlawful to mark a product with an expired patent number. See
Pequignot v. Solo Cup Co., 608 F.3d 1356, 1358, 1361 (Fed. Cir. 2010) (holding that a “nowexpired patent” was “unpatented” under 35 U.S.C. § 292(a), which prohibits marking unpatented
products with the word “patent” “for the purpose of deceiving the public”). The Leahy-Smith
America Invents Act clarified that an expired patent does not violate § 292. See Pub. L. No. 112-
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in pleadings.54 Five additional patent numbers were excluded because they
contained typographical errors,55 and one final patent was erroneously
asserted long after it had expired for failure to pay maintenance fees.
For each of the remaining 421 patents, I collected a variety of data to
determine when the patents were asserted, how many times they were
asserted, and against whom they were asserted. In order to compare the
relative ages of patents asserted by practicing and nonpracticing entities, I
categorized the party enforcing each patent using patentee classes developed
by Mark Lemley and Nathan Myhrvold.56 Finally, in order to compare the
diversity of technology enforced by practicing and nonpracticing entities, I
categorized the invention claimed in each patent using technology and
industry classes developed by Lemley, John Allison, and Joshua Walker.57
1. Prosecution Data
First, to calculate each patent’s term, I determined the date on which
each patent was filed and issued.58 Specifically, I identified the filing date of
each patent’s application, or of the earliest United States parent application59
to which it claims priority.60 I also identified whether each patent’s owner

29, § 16(b)(3), 125 Stat. 284, 329 (2011) (amending 35 U.S.C. § 292(c) (2006)) (“The marking of a
product . . . with matter relating to a patent that covered that product but has expired is not a
violation of this section.”).
54 Seven patents were cited as prior art in an answer or declaratory judgment complaint.
Eleven were cited for other extraneous reasons in pleadings bringing claims for trademark
infringement, copyright infringement, unfair competition, or breach of contract.
55 Westlaw’s Derwent LitAlert database was rife with erroneously transcribed patent numbers.
In the vast majority of cases, I was able to reverse-engineer the correct patent number. The vast
majority of corrected patent numbers issued within the study period, but a small minority did not.
56 See Allison, Patent Quality and Settlement, supra note 1, at 683-84 (describing the typology
of entity-status classes developed by Lemley and Myhrvold).
57 See id. at 685 tbl.2 (defining nine technology areas, including software, optics, and electronics, and thirteen industry areas, including pharmaceuticals, communications, and transportation). This Article does not address my findings with respect to technology and industry in detail.
Those results are tentatively reserved for a forthcoming companion piece.
58 Both dates are found on the patent document itself.
59 Prior foreign filing dates do not start the twenty-year term. 35 U.S.C. § 154(a)(3).
60 Many patent applications blossom over time into a “family” of divisional, continuation,
and continuation-in-part child applications, each of which may in turn spawn their own children,
and so on. See 35 U.S.C. §§ 120–121; 37 C.F.R. § 1.53(b), (d) (2011) (permitting each of these
types of applications). It is frequently these subsequent applications, rather than their parents,
which ultimately issue patents. See Mark A. Lemley & Kimberly A. Moore, Ending Abuse of Patent
Continuations, 84 B.U. L. REV. 63, 70 (2004) (noting that over half of all litigated patents issue
from continuation applications); Mark A. Lemley & Bhaven Sampat, Is the Patent Office a Rubber
Stamp?, 58 EMORY L.J. 181, 190-93 (2008) (finding that, taking continuation applications into
account, the PTO grants patents to more than 70% of applicants).
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made all three maintenance fee payments and, if not, on which date the
patent prematurely fell into the public domain.61
2. Litigation Data
Next, I collected enforcement data for each patent.62 Specifically, I identified:
(a) the date each patent was first enforced: the filing date of the earliest
complaint alleging infringement of the patent or seeking a declaration that
the patent was not infringed or was invalid;63
(b) the date enforcement of each patent ceased: the date on which the very
last claim asserting infringement of the patent, or seeking a contrary
declaration, was resolved;64

61 Generally, patent owners are given a six-month grace period to pay their maintenance fees,
and failure to pay beyond that period results in the patent’s expiration. 35 U.S.C. § 41(b). But, a
payment made within twenty-four months after the grace period may be accepted if the delay was
“unintentional” or “unavoidable.” Id. § 41(c).
62 To locate the docket number of each case asserting a given patent, I cross-referenced results from three databases: (i) each case in which the patent was reported as asserted in Westlaw’s
Derwent LitAlert database, (ii) each additional case, if any, from which a document was listed on
Westlaw’s “citing references” for each studied patent, and (iii) each additional case, if any,
returned by a search for the patent’s number on the Stanford IP Litigation Clearinghouse. To
exclude false positives and gather litigation statistics from true assertions, I relied on PACER
docket reports for cases filed prior to 2000 and Stanford IP Litigation Clearinghouse docket
reports for cases filed in 2000 or later. The dockets for three cases filed pre-2000 were, for
unknown reasons, not available via PACER. See Nos. 97-CV-285 (D. Nev.); 96-CV-1040 (D.
Nev.); 95-CV-782 (W.D. Tex.). Because I could not determine when these three cases were resolved, I excluded the patents at issue in these cases from the analyses related to litigation end dates.
63 Patents can, of course, be enforced without filing litigation. For a detailed discussion, see
infra Section III.C.
64 In suits resolved by settlement (the vast majority of cases), I identified the date on which
the court granted the parties’ stipulated motion for dismissal or for a consent judgment. In suits
resolved in the accused infringers’ favor, I identified the date of the jury’s verdict; the date on
which the court granted the accused infringer’s dispositive motion to dismiss (e.g., following a ruling
that the patentee is not the true owner of the patent-in-suit), motion for summary judgment, or
motion for judgment as a matter of law. In the event of an appeal, I identified the date of the
affirmance of any of the aforementioned motions. In suits resolved in the patentee’s favor, I
identified the date on which the court awarded damages or an injunction, or, in the event of an
appeal, the date of affirmance of these remedies. Finally, for three suits in which an unsuccessful
petition for certiorari to the Supreme Court was filed, I identified the date certiorari was denied.
I did not identify the date on which the case was “terminated”—i.e., the date on which the
court administratively closed the case. Doing so would have counted days, months, or years spent
litigating nonsubstantive post-trial or post-judgment issues, like motions for attorneys’ fees and
motions for sanctions. Also, in many cases, other claims (including claims for infringement of
other patents) continued after claims asserting the studied patent had been resolved. In these
multiclaim cases, I identified the date specific to the claim for infringement of (or declaratory
judgment claim against) the studied patent.
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(c) the total number of suits in which each patent was asserted: the total
number of unique docketed cases in which the patentee asserted the patent
or alleged infringers sought declaratory relief from an imminent assertion,
excluding parallel case pairs and consolidated cases other than multi-district
litigation;65
(d) the total number of accused infringers against which each patent was asserted:
the total number of unique parties against which an infringement claim has
been filed or which filed a claim seeking a declaration of relief;66
(e) litigation outcomes: whether each patent was ever adjudicated on the
merits and, if so, whether the outcome was a finding of infringement,
noninfringement, or invalidity;67 and
65 Accused infringers will often file suit preemptively, seeking a declaration of noninfringement or invalidity. The vast majority of these suits are filed close in time to a mirrorimage patent infringement complaint brought by the patent owner. In fact, until recently, courts
would only exercise jurisdiction over declaratory judgment actions in which the plaintiff held “a
reasonable apprehension of imminent suit.” Teva Pharm. USA, Inc. v. Pfizer, Inc., 395 F.3d 1324,
1333 (Fed. Cir. 2005), abrogated by MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007).
Patentees and accused infringers often race to the courthouse (albeit in different districts) in hopes
of ultimately consolidating both suits in their forum of choice. See Kimberly A. Moore, Judges,
Juries, and Patent Cases—An Empirical Peek Inside the Black Box, 99 MICH. L. REV. 365, 404 (2000)
(stating that infringers file declaratory judgment suits before patentees file infringement suits in
order to choose the forum they think will be most favorable). As declaratory judgment plaintiffs,
accused infringers may also hold a psychological advantage with juries. See id. at 406 fig.12
(showing that patentees win 68% of jury trials in patentee-filed infringement actions, but only 38%
of jury trials in accused infringer–filed declaratory judgment actions). These case pairs typically
involve the same parties and proceed in tandem. I counted these case pairs as one suit since, for all
intents and purposes, they are. In a similar fashion, ITC investigations often coincide with a
patent infringement suit filed contemporaneously in district court. Again, because an ITC
investigation brought in parallel with a patent infringement action is in essence one suit, I counted
them as such.
Finally, I merged data for individual suits that were so similar and contemporaneous that they
were consolidated into a single action. The sole exception I made to this rule was for multi-district
litigations (MDLs), which pull together a large number of cases filed over a long period of time.
My sample included three MDLs: In re Rembrandt Techs., LP, Patent Litig., 493 F. Supp. 2d 1367,
1369 ( J.P.M.L. 2007) (consolidating fifteen suits in three different federal districts); In re Acacia
Media Techs. Corp. Patent Litig., 360 F. Supp. 2d 1377, 1378-79 ( J.P.M.L. 2005) (consolidating
twenty suits in five districts); and In re Pabst Licensing, GmbH Patent Litig., No. 99-1298, 2001 WL
797315, at *1 (E.D. La. July 12, 2001) (addressing seven motions filed in response to the consolidation of four civil actions by the Panel on Multi-District Litigation).
66 I excluded “John Doe” parties from this number.
67 I did not count default judgments as “adjudications.” To make the most of extremely limited data, the litigation outcomes reported below are restricted to those at the district court level.
The data is not adjusted to account for appellate outcomes. Analysis of district court outcomes
alone is not uncommon in the patent litigation literature. Cf. Michael J. Mazzeo et al., Excessive
or Unpredictable? An Empirical Analysis of Patent Infringement Awards 27-28 ( June 17, 2011)
(unpublished manuscript), available at http://ssrn.com/abstract=1765891 (examining district court
damages awards without examining subsequent changes to damages award after appeal). The
litigation outcome data also reflects the fact that a small number of patents (four product-
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(f) suit-specific and assertion-specific statistics for litigation ongoing six years
prior to patent expiration: the start date, date of resolution, and number of
accused infringers for each suit ongoing within at least six years of the
patent-in-suit’s expiration, and the start date and date of resolution of each
individual infringement claim in those suits.
3. Assignment History and NPE Status
In order to compare enforcement timing among practicing and nonpracticing patentees, I also collected information concerning each patent’s
owner, including:
(a) each patent’s chain of ownership: the number of times each patent
changed hands between the time it was issued and the time it was first
asserted in court, including the dates of the first assignment after issue and
the last assignment prior to litigation;68 and
(b) the NPE status of each party asserting a patent: whether the entity asserting each patent sold a product and, if not, what kind of NPE it was.
For the purpose of comparing enforcement timing, I adopted the patentee
classification system developed by Mark Lemley and Nathan Myhrvold,
which is outlined below in Table 2. Only Class 8 patentees—those that
produce a product—are “practicing” entities. Patentees whose status I could
not determine fall under Class 10 and were excluded from my sample.69

company patents and one NPE patent) were adjudicated multiple times with varying results. See
Timing Dataset.
68 I obtained this data from the PTO’s Assignment on the Web for Patents (AOTW-P). See
Assignments on the Web > Patent Query, U.S. PATENT & TRADEMARK OFFICE, http://assignments.
uspto.gov/assignments/?db=pat (last visited Mar. 15, 2013). Patent owners generally do, but are
not required to, record assignments with the PTO. See Carlos J. Serrano, The Dynamics of the
Transfer and Renewal of Patents, 41 RAND J. ECON. 686, 690 & n.14 (2010) (noting anecdotal
evidence that patent transfers and related transactions are often recorded at the PTO even though
recordation is not mandatory). Assignments recorded with the PTO within three months protect
against ownership claims of subsequent purchasers. 35 U.S.C. § 261 (2006). However, there are
no other benefits or penalties associated with recording. To ensure that my data reflects only true
transfers of ownership, I excluded any assignments that occurred merely as a result of an owner’s
name change or minor corporate reorganization. In a number of instances, the party asserting a
patent in litigation did not match the last-recorded owner on file with the PTO. In the vast
majority of such cases, I was able to determine from pleadings or other litigation documents
whether the party was an owner by unrecorded assignment or simply the last-recorded owner’s
exclusive licensee. I excluded the few instances in which I was unable to determine the party’s
status as unrecorded owner or exclusive licensee.
69 Following Allison, Lemley, and Walker, I excluded Class 10 patents from my study. However, as they note, “[t]hat a diligent search could not identify what an entity did suggests that it is
likely some form of NPE.” Allison, Patent Quality and Settlement, supra note 1, at 684 n.28. I
excluded three patents because I was unable to determine their owners’ NPE statuses and also
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Strictly speaking, all other classes are “nonpracticing” entities. Though
NPEs are by no means homogeneous, for simplicity’s sake many of the
results detailed below are reported for NPEs as a whole. Where practicable,
however, results are broken down by entity class so that the reader may
determine for herself where to draw the line between NPEs and “trolls.”
Table 2: Entity-Status Classes70
Entity Class
1
2
3
4
5
6
7
8
9
10
11
12

Description
Acquired patents71
University heritage or tie
Failed startup
Failed product company
Individual inventor–started company72
University, Government, or NGO73
Start-up, pre-product
Product company
Individual inventor(s)
Undetermined
Industry Consortium
IP subsidiary of a product company

excluded four individually owned patents that were exclusively licensed to patentees of indeterminable NPE status.
70 See Allison, Patent Quality and Settlement, supra note 1, at 683-84 & tbl.1 (describing the
typology of entity status classes developed by Lemley and Myhrvold).
71 There is a fine line between Class 1 and Classes 3 and 4 because many acquired patents
come from failed product-producing companies and start-ups. In this study, I categorized a
patentee as Class 3 or Class 4 when the entity filing suit was the failed company itself, and Class 1
when the entity filing suit was a distinct IP-holding firm that acquired the patent, even if that
firm’s entire portfolio appeared to be salvaged from one failed company. For example, I categorized T.M. Patents, LP—a firm created to hold patent assets from the failed Thinking Machines
Corporation—as Class 1, not Class 4. Because there is only a minor distinction between a failed
company that began to assert its patents in its own name and a failed company that first reorganized into an LLC or LP before doing the same, I report below combined results for Classes 1,
3, and 4.
72 In this class and in Class 9, I included patents owned by licensing companies started by
deceased inventors’ heirs and patents owned by such heirs, respectively. A number of patents were
litigated by family members of the named inventor after the inventor’s death. See, e.g., First
Amended Complaint for Declaratory Judgment and Other Relief and Demand for Jury Trial at 2,
4, 6-7, Black & Decker, Inc. v. Billy Star Holdings, Ltd., No. 08-1261 (D. Minn. May 12, 2008)
(asserting a lawsuit against a licensee for failing to pay royalties to plaintiff who inherited patent
from his deceased father, the original inventor).
73 In my sample, it turned out that all Class 6 patents were owned by universities. See Timing
Dataset.
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Because many patents were owned at the time of suit by an entity of one
class but were asserted by an exclusive licensee of another, I identified the
patent owner and the party asserting the patent in each litigation—i.e., the
“patentee.” Unless stated otherwise, the results reported in this Article
identify the NPE status of the party acting as patentee in court, even if that
party is the patent’s exclusive licensee and thus, strictly speaking, is not its
owner.74 Figure 1 below shows the disparity between patent ownership and
responsibility for enforcement. Notably, a significant number of NPEowned patents were exclusively licensed to product-producing patentees.
All university-owned patents in my sample, and more than half of the
individually-owned patents, were at the time of assertion exclusively
licensed to product-producing companies that acted as plaintiffs or declaratoryjudgment defendants.75 Firms organized for the purposes of exploiting
unused patents—patent acquisition firms, firms holding the IP assets of
failed companies, and inventor-affiliated licensing firms—therefore account
for nearly two-thirds of all NPE-asserted patents.76 More controversial
NPEs account for a small minority of NPE patents and do not drive the
results reported below.77
Finally, it is worth noting that by happenstance my random sample did
not select any patents owned by class 5 patentees Ronald Katz (i.e., Ronald
A. Katz Technology Licensing, LP) or Jerome Lemelson (i.e., Lemelson
74 This convention is used consistently in the literature. See Allison, Extreme Value, supra note
1, at 10 (categorizing “the patent plaintiff”).
75 See Timing Dataset. In addition, one individually owned patent was asserted by a patent
acquisition firm. Only one patent originally owned by a university found its way into the hands of
another NPE. See id., U.S. Patent No. 5,260,093. Additionally, four patents were transferred in
between suits to entities of a different class. One patent, initially asserted by a product company,
was later assigned to an intellectual property–holding subsidiary. See id., U.S. Patent No.
5,289,183. Another was asserted by a product company that subsequently failed and was reborn as
a litigation-oriented enterprise. See id., U.S. Patent No. 5,213,670. A third was asserted by an
individual inventor who later assigned the patent to an acquisition firm. See id., U.S. Patent No.
5,279,051. And a final patent was initially asserted by a start-up company that subsequently failed
and assigned the patent to a patent acquisition firm. See id., U.S. Patent No. 5,291,302. In order to
compare litigation timing strictly across entity type, I divided these patents into multiple data
points, one for each period of litigation supervised by a new entity type.
76 See Allison, Extreme Value, supra note 1, at 24 (referring to “licensing companies in the
business of buying up and enforcing patents” as “‘trolls’ by virtually anyone’s definition”); Ball &
Kesan, supra note 3, at 14-15 (noting that licensing firms “are among the parties most frequently
cited as the most prominent form of patent ‘troll’”). Collectively, these patentee types account for
57 of 88 NPE-asserted patents, or 65%. See infra Table 7. Acquired patents account for 38 of 88, or
43%. Patents asserted by inventor-affiliated licensing companies account for the remaining 19 of
88, or 22%. Id.
77 See supra notes 9-10. As discussed later, see infra paragraph accompanying note 99, virtually
all individually owned patents were asserted relatively early in the patent term and, therefore, also
do not drive the results reported below.
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Medical Education & Research Foundation), although several litigated
patents owned by both were issued within the study period.78 Katz and
Lemelson are perhaps the two most famous and most prolific patent
plaintiffs of all time, and they have what can conservatively be described as
an outsized impact on patent litigation statistics. Both, and especially Katz,
have a history of filing extremely large numbers of suits against extremely
large numbers of accused infringers, and authors of previous studies have
grappled with whether to exclude their statistics.79 The addition of even one
Katz patent to my sample—e.g., U.S. Patent No. 5,255,309 or U.S. Patent
No. 5,251,252,80 both of which have been asserted in about eighty suits—
would have significantly increased the per-suit and per-assertion results
reported below.

78 Katz and Lemelson asserted at least eight patents issued during the study period. For
Katz’s asserted patents, see U.S. Patent No. 5,297,197 (filed June 8, 1992); U.S. Patent No.
5,259,023 (filed Dec. 3, 1991); U.S. Patent No. 5,255,309 (filed Dec. 3, 1991); U.S. Patent No.
5,251,252 (filed Oct. 21, 1991); U.S. Patent No. 5,224,153 (filed Apr. 5, 1991); and U.S. Patent No.
5,218,631 (filed June 8, 1990). For Lemelson’s asserted patents, see U.S. Patent No. 5,283,641 (filed
June 16, 1993) and U.S. Patent No. 5,231,259 (filed Aug. 14, 1992). See generally Timing Dataset.
79 In a study of patents litigated eight or more times between 2000 and 2007, Katz alone
accounted for 60% of all studied lawsuits. See Allison, Extreme Value, supra note 1, at 26 (noting the
enormity of the “Katz effect,” but ultimately deciding to retain Katz-related patents in the
empirical analysis).
80 See supra note 78.

1328

[Vol. 161: 1309

University of Pennsylvania Law Review

Figure 1: Patent Owner–Patentee Histogram81
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4. Technology and Industry Categories
Lastly, I categorized each patent by technology and industry. Rather
than using the PTO classification system, I followed Allison, Lemley, and
Walker’s taxonomy, which includes nine nonexclusive technology categories
and thirteen nonexclusive industry categories listed below in Table 3.82

81 See Timing Dataset. These statistics are generally consistent with Colleen Chien’s findings
in a study of litigated patents issued in 1990, though I find a higher percentage of product
company–asserted patents. See Chien, supra note 24, at 309, 314 (finding, in a study of 659
litigated patents issued in 1990, that 73% were litigated by product-producing companies, 9% by
“patent assertion entities,” and 18% by individual inventors). For the precise breakdown of NPEasserted patents among the various classes, see infra Table 7.
82 See Allison, Patent Quality and Settlement, supra note 1, at 684-85 (describing the taxonomy
I apply here). In prior work, Allison and Lemley have criticized the PTO’s rather byzantine
classification system. See John R. Allison & Mark A. Lemley, Who’s Patenting What? An Empirical
Exploration of Patent Prosecution, 53 VAND. L. REV. 2099, 2114 (2000) (criticizing the PTO’s
classification system as unreliable and imprecise when grouping technologies together).
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Table 3: Technology and Industry Areas83
Technology Categories
1. Software
2. Pure software
3. Software business method
4. Mechanical
5. Electronics
6. Optics
7. Imaging
8. Biotechnology
9. Chemistry

Industry Categories
1. Computer
2. Semiconductor
3. Electronics
4. Medical
5. Pharmaceutical
6. Biotechnology
7. Chemical
8. Communications
9. Transportation
10. Energy and utility services
11. Financial
12. Consumer goods and services
13. Construction

Much of this data I have reserved for future research. I do, however,
report results below that distinguish among “software,” “high-tech,” “medical
device,” “pharmaceutical,” and “biotechnology” patents. Software patents,
as used in this study, are those that fall within technology categories 1, 2, or
3, regardless of the industry in which they are employed.84 I label “hightech” all patents covering computer, electronics, and/or telecommunications
technology, including all software patents. These patents generally fall
within one or more of technology categories 1-3 and 5-7, and one or more of
industry categories 1-4 and 8-9. Finally, medical device, pharmaceutical, and
biotech patents are classified as industry categories 4, 5, and 6, respectively.
Medical device patents touch on almost every technology category, though
most are strictly or primarily mechanical in nature. Some medical device
patents—for example those covering computer- or electronically-assisted
medical procedures—overlap with technology categories 1-3 and 5-7.
II. RESULTS
A. Two Patent Terms
I begin my analysis by investigating the relative ages of patents asserted
by practicing and nonpracticing entities. To make this comparison, however,

83
84

See supra note 82.
Categories 2 and 3 are both subsets of category 1. Allison, Extreme Value, supra note 1, at 6-7.
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I must adjust for the fact that patents in my sample may have one of two
different patent terms. All patents in this study issued just before a major
event in the history of patent law: the United States’ 1994 ratification of the
Agreement on Trade-Related Aspects of Intellectual Property Rights.85 To
comply with the new international obligations, Congress changed the way
United States patent law calculates the patent term for the first time since
1952. The legislation, effective June 8, 1995, altered the patent term from
seventeen years from issue to twenty years from filing.86 Importantly, the
legislation created a hybrid calculation for unexpired patents issued before
or pending on June 8, 1995.87 Every patent issued during the study period is
included in this group. These patents receive a term of either seventeen
years from issue or twenty years from filing, whichever is longer.88
Thus, barring invalidation or a missed maintenance fee payment, every
patent in this study received a term of at least seventeen years from issuance
and at least twenty years from filing.89 The percentage of patents falling in
each category is shown below in Table 4. For product-producing companies
and NPEs alike, the average duration of prosecution among studied patents
was nearly three years.90 Nonetheless, to account for these slight variations
in the patent terms, I primarily report patent age measured in years prior to
expiration, whether the term is calculated as seventeen years from issue or
twenty years from filing.91

85 The United States adopted the Uruguay Round Agreement of the General Agreement on
Tariffs and Trade. See supra note 41. The Uruguay Round Agreement included the Agreement on
Trade-Related Aspects of Intellectual Property Rights (TRIPS). Uruguay Round Agreements
Act, Pub. L. No. 103-465, § 101(d)(15), 108 Stat. 4809, 4814-15 (1994) (codified at 19 U.S.C.
§ 3511(d)(15) (2006)); Agreement on Trade-Related Aspects of Intellectual Property Rights
[hereinafter TRIPS agreement], adopted by United States Dec. 8, 1994, 18 U.N.T.S. 299; see also
Evelyn Su, Comment, The Winners and the Losers: The Agreement on Trade-Related Aspects of
Intellectual Property Rights and Its Effects on Developing Countries, 23 HOUS. J. INT’L L. 169, 185
(2000) (describing the history of the TRIPS agreement).
86 Compare 35 U.S.C. § 154(a)(2) (providing that the term of a patent currently lasts twenty
years from filing), with 35 U.S.C. § 154 (1988) (providing that the term of a patent lasted
seventeen years from issue).
87 35 U.S.C. § 154(c)(1) (2006).
88 Id.
89 Patents that issued from applications less than three years old received a longer term under the twenty-years-from-filing formulation. Patents that issued from applications spending
longer than three years at the PTO received a longer term under the seventeen-years-from-issue
formulation.
90 NPE patents spent an average of 1094 days at the PTO (almost exactly three years).
Product-company patents spent an average of 1089 days, just five fewer days. See Timing Dataset.
91 When measuring backwards from expiration, I use the date the term expired or would have
expired for patents that fell into the public domain prematurely.
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Table 4: Patent Term92
Event
20 Years from Filing
17 Years from Issue
Failure to Pay Maintenance Fee
Invalidated

Percentage of Patents
Possible Term Actual Expiration
68.7%
56.3%
31.3%
25.4%
-14.3%
-4.0%

B. Timing Per Patent
Figures 2 and 3 below show the relative timing of patent enforcement
across NPE status on a per-patent basis. Figure 2 is a histogram of the dates
on which patents were litigated for the first time, measured backward from
the date each patent’s term ended. Figure 3 is a histogram of the dates on
which litigation asserting patents ended once and for all, again measured
backward from the date of expiration. The results are dramatic. As shown
below in Table 5, on average, product-producing companies finish enforcing
their patents before NPEs even begin.
Product producing–company litigation and NPE litigation follow opposing trends. On average, product-producing companies overwhelmingly
begin litigating their patents early in the patent term, more than twelve
years before expiration,93 and overwhelmingly finish with many years of
patent life remaining, more than nine years from expiration.94 NPEs, on the
other hand, begin litigating their patents much later in the term, less than
nine years from expiration on average,95 and overwhelmingly finish in the
final few years of the patent term, with an average of 4.4 years (and a
median of under three years) remaining.96
These opposing trends intersect one another about three to five years
prior to expiration. With five years of patent life remaining, productproducing companies have started (and in most cases finished) litigating
over 93% of their (asserted) patents, while over 31% of NPE patents have
92
93
94
95
96

See Timing Dataset.
12.1 years, with a standard deviation of 4.4 years and a median of 12.7 years. See id.
9.2 years, with a standard deviation of 4.9 years and a median of 9.9 years. See id.
8.8 years, with a standard deviation of 5.2 years and a median of 8.5 years. See id.
4.4 years, with a standard deviation of 5.0 years and a median of 2.8 years. See id. These
statistics are comparable to prior estimates. See John R. Allison & Mark A. Lemley, Empirical
Evidence on the Validity of Litigated Patents, 26 AIPLA Q.J. 185, 237 (1998) (finding that patent suits,
on average, are resolved 12.3 years from the application date of the patent-in-suit); Risch, supra
note 1, at 490 (finding, among the most litigious NPEs, an average delay of 8.3 years between
issue and filing a first complaint).
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not yet been asserted. With three-and-a-half years of term remaining,
product-producing companies have finished asserting more than 86% of
their patents, while more than 59% of NPE patents remain in, or will soon
enter, the court system. Though they constitute just one-fifth of all patentees,
NPEs asserted almost 55% of patents litigated for the first time within five
years of expiration and over 53% of patents in litigation resolved within
three-and-a-half years of expiration.

Figure 2: Years from First Suit to Expiration97
60

Prod. Co.
IP Subsid.
Inventor Licensing Co.

50

New Startup
Individual
Acquired/Failed

Patents

40
30
20
10
0
>17

17 15.5

14 12.5 11 9.5

8

6.5

5

3.5

2

≤0.5

Years Until Expiration

97 See Timing Dataset. For a breakdown of specific findings across patentee classes and the
patent term, see infra Table 7.
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Figure 3: Years from Cessation of All Litigation to Expiration98
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Individual

50

New Startup
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IP Subsid.
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40
30
20
10
0
>17

17

15.5

14

12.5

11

9.5
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6.5
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2
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Years Until Expiration

Data on the chain of ownership of these litigated patents in Table 5 sheds
additional light on NPEs’ relatively long delay in filing suit. NPE-asserted
patents, particularly those acquired from other firms (failed or otherwise),
change hands more frequently over a longer period of time than their
counterparts litigated by product-producing companies. Moreover, once
NPE-asserted patents reach the patentee who will ultimately assert them in
court, they sit on average for another three years before they are litigated.
As a whole, NPE-asserted patents are three times more likely to have
changed hands between issue and enforcement than product company–
asserted patents.99 Litigant classes 1, 3, and 4, collectively, are more than
four times as likely to be asserting a patent that has been transferred
between owners post-issue. And assigned patents asserted by these classes
have changed hands roughly 50% more often per patent. Patents do not
reach acquisition firms until about 9.5 years after issue, and these firms wait
2.4 additional years on average before filing suit. Other NPEs fare little
better. Inventor-affiliated licensing companies generally do not form until
about six years after issue and, on average, wait more than five additional
years before filing suit. And, on average, patents reach product-producing
companies’ licensing subsidiaries about eight years after issue and sit for an
98
99

See Timing Dataset.
See id. These statistics likely understate the disparity in the rate at which productcompany and NPE patents are sold because many product-company assignments are the result of
mergers, acquisitions, and spin-offs involving all of the patent owner’s assets, not just its patent
rights. See generally Chien, supra note 24, at 310-11 (discussing the various ways in which patents
can be conveyed).
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additional four years before assertion. Individual inventors, by contrast, file
suit quickly on almost the exact same timeline as product-producing companies.
Thus, with the notable exception of those claims litigated by individuals,
NPE-asserted patents take a long, circuitous path from the PTO to the
courthouse that often spans more than a decade and includes multiple prior
owners. This finding strongly suggests that it makes little sense to discuss
the percentage of NPE litigation among all suits filed. NPEs do not obtain
patents until the patent term is half-spent and hold their patents for several
years more before filing suit, perhaps while waiting for emerging industries
to mature.100 Thus, the bare statistic that NPEs account for only about onefifth of all patents litigated obscures the fact that NPEs account for the
majority of patents litigated in the final few years of the term—the only
portion of the term when NPEs are actively asserting their patent rights.

100 Again, my findings are consistent with prior estimates in the literature. See Risch, supra
note 1, at 490 (finding that, among patents asserted by the ten most litigious NPEs, the average
time span between issuance and last assignment was seven years).
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3.0
2.3
5.2
2.4
3.1
2.9 yrs

0.3931

1.4
0
1.7
2.9
2.3
1.3 yrs

0.0085

5.4
7.2
4.1
6.6
6.0
4.2 yrs

0.0163

2.25
1
1.67
2.1
1.9
1.4

0.0014

5.4
12.5
14.9
67%
9.3
8.5
11.4
14%
3.1
14.7
17.2
71%
1.5
16.1
19.4
87%
4.4
13.2
16.1
62%
9.2 yrs
8.6 yrs
11.6 yrs
21%

< 0.001
< 0.001
< 0.001
< 0.001

8.3
9.7
12.1
12.1
5.7
8.6
7.9
9.95
12.4
6.7
10.8
14.2
< 0.001
< 0.001
< 0.001
8.8
9.0
11.9

Avg. litig. start
Until exp’n
From issue
From filing
Avg. litig. end
Until exp’n
From issue
From filing
Percent assigned
Assignment data
Total assigns.
Time from
issue to first
assign.
Time from
first to last
assign.
Time from
last assign. to
assertion

12.1 yrs
5.7 yrs
8.7 yrs

Individual
(Class 9)
Inventor
Licensing
Co.
(Class 5)
Acquired/
Failed
(Classes 1,
3-4)
p-value
All
NPEs
Prod.
Co.
(Class 8)

Table 5: Litigation Timing and Assignment History101

IP
Subsid.
(Class 12)

101

101 See Timing Dataset. All statistical analysis reported in this paper was conducted using the
Stata v.10.0 t-test, Pearson’s chi-squared, and Fisher’s exact functions, as appropriate. As explained
above, the “percent assigned” statistics attempt to count only “true” transfers of ownership, not
mere name changes or minor corporate reorganizations (both of which appear in PTO assignment
records). See supra note 68. The percentage of patents assigned in the “Acquired/Failed” classes
is not 100% because five patents remained in the name of their failed owner. The percentage of
patents assigned in the “Individual” class is not zero because there were three assignments between
joint inventors—for example, one co-owning joint inventor assigned his rights to the other in
order to consolidate ownership of the patent in one inventor’s name.
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C. Per Suit and Per Assertion

The results above actually understate the true magnitude of late-term
NPE enforcement. As shown below in Table 6, NPEs are far more litigious
on average than product-producing companies. Overall, NPEs file more
than twice as many suits per patent and assert each patent against more
than four times as many alleged infringers.102 Moreover, NPEs are even
more litigious late in the patent term. Per patent litigated in the last three
years of its term, NPEs file two-and-a-half additional suits against thirteen
additional infringers.103
Table 6: Relative Litigiousness104

Overall
Suits/Patent105
Assertions/Patent
Litig. complete, more than 3 yrs. from exp’n
Suits/Patent
Assertions/Patent
Litig. ongoing, less than 3 yrs. from exp’n
Suits/Patent
Assertions/Patent
p-value

Prod. Co.

NPE

p-value

1.5
2.9

3.6
12.3

< 0.001
< 0.001

1.4
2.6

1.7
5.0

2.6
5.1
< 0.001
< 0.001

5.2
18.1
< 0.001
< 0.001

Taking into account NPEs’ relative litigiousness, NPEs’ dominance of
late-term patent litigation grows considerably, as does their share of overall
enforcement. Figure 4 below is a histogram of lawsuit filing dates for all
suits filed within six years of the patent-in-suit’s expiration. Figure 5 is a
histogram of lawsuit resolution dates for all suits resolved within six years
of the patent-in-suit’s expiration. Both show a significant increase in NPEs’
late-term domination viewed on a per-suit basis. NPEs account for the
102 See Timing Dataset. James Bessen et al. found a mean of 15.3 (and a median of 5) accused
infringers per suit in a study of patent infringement cases filed by NPEs between 1990 and 2010.
James Bessen et al., The Private and Social Costs of Patent Trolls 4, 31 tbl.2 (Bos. Univ. Sch. of Law
Working Paper No. 11-45, 2011), available at http://ssrn.com/abstract=1930272.
103 See Timing Dataset. Naturally, both product-producing companies and NPEs assert their
oldest patents still in litigation more times than average.
104 See Timing Dataset.
105 Some studied patents were asserted together in the same suit, and all “per suit” data
accounts for this fact. The rates reported in this Table, however, report the average number of suits
in which each patent was asserted, whether or not another studied patent was asserted in the same suit.
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majority of all new patent filings in each of the last five years of the patent
term and account for more than 67% of all patent suits filed within five
years of the patent-in-suit’s expiration. NPEs similarly account for the
majority of patent suits resolved within each of the last four years of the
patent term and account for more than 70% of all patent suits resolved
within three years of the patent-in-suit’s expiration.

Figure 4: Years from Each Suit’s Filing
to Patent-in-Suit’s Expiration106
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106

See Timing Dataset.
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Figure 5: Years from Each Suit’s Resolution
to Patent-in-Suit’s Expiration107
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Finally, viewed per accused infringer—or per “assertion”—NPEs’ domination of late-term patent litigation becomes even more overwhelming.
Figure 6 below is a histogram of filing dates for all assertions filed within
six years of the asserted patent’s expiration. Figure 7 is a histogram of
resolution dates for all assertions resolved within six years of the patent-insuit’s expiration. The results in both figures are dramatic. NPEs account for
the majority of all new patent assertions in each of the last six years of the
patent term and, in particular, account for more than 83% of all patent
assertions filed within five years of the patent-in-suit’s expiration. NPEs
similarly account for the majority of patent assertions resolved within each
of the last five years of the patent term and, particularly, for more than 83%
of all patent assertions resolved within three years of expiration.

107

See id.
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Figure 6: Years from Each Assertion’s Filing to
Patent-in-Suit’s Expiration108
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Figure 7: Years from Each Assertion’s Resolution to
Patent-in-Suit’s Expiration109
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As summarized below in Table 7, by comparing patents litigated at a
similar age (rather than all litigated patents), it is clear that NPE-asserted
patents are the overwhelmingly dominant source of patent litigation in the
final years of the patent term. NPEs assert the majority of new patents, file
roughly two-thirds of new suits and file over four-fifths of new assertions in
the final five years of the patent term. They are also responsible for almost
identical percentages of patents enforced, and suits and assertions resolved,
within three years of expiration. Moreover, the lion’s share of late-term
NPE litigation is brought by patent acquisition firms, firms holding the IP
remnants of failed companies, and inventor-affiliated licensing firms.
Collectively, these classes account for about 92% of NPE suits active within
three years of the patent expiration. Thus, while prior studies may have
shown that “NPEs file only a small fraction of all patent infringement
suits,”110 my results indicate that NPEs—specifically those NPEs most
associated with litigation abuse111—are responsible for an enormous fraction
of infringement claims brought late in the patent term, precisely when
litigation seems most abusive.112

110
111
112

Risch, supra note 1, at 466.
See supra note 76.
See Risch, supra note 1, at 490 (“The longer [NPEs] waited, the more like mythical trolls
their behavior might appear . . . .”).

Total Patents
Enforcement ceased
w/in 3 yrs. of exp’n
Enforcement
initiated w/in 5 yrs.
of exp’n
Total Suits
Suits resolved w/in
3 yrs. of exp’n
Suits filed w/in 5
yrs. of exp’n
Total Assertions
Assertions resolved
w/in 3 yrs. of exp’n
Assertions filed
w/in 5 yrs. of exp’n
88
48
(54.5%)
28
(31.8%)
288
143
(49.6%)
110
(38.2%)
1069
654
(61.2%)
557
(52.1%)

23
(6.9%)
456
60
(13.2%)
53
(11.6%)
964
132
(13.7%)
111
(11.5%)

All
NPEs

333
38
(11.4%)

Prod. Co.
(Class 8)

447
367

< 0.001

154

140

211

709
< 0.001

19

81

< 0.001

19

45

6

12

19

Inventor
Licensing
Co.
(Class 5)

112

189

18

31

38

Acquired/
Failed
(Classes 1,
3-4)

< 0.001

< 0.001

< 0.001

p-value

Table 7: Late-Term Litigation Summary113
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0

3

0

0

1

0

0

1

New
Startup
(Class 7)

29

32

82

4

5

37

2

2

22

Individual
(Class 9)

7

35

64

6

7

16
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3

8

IP
Subsid.
(Class 12)
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113

113 See Timing Dataset. The “total suits” data was adjusted to account for the fact that some
studied patents were asserted together in one suit.
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D. Technology Areas and Litigation Outcomes
The results reported above suggest that the final few years of the patent
term primarily benefit NPEs. Compared to product-producing companies,
NPEs as a whole—and especially firms that hold patents purely for enforcement—assert more patents, in more suits, and against more accused
infringers late in the patent term. In fact, as Table 6 shows, NPEs become
more aggressive as their patents age. NPE status and litigiousness, however,
are not the only traits commonly associated with patent trolls. In this
Section, I investigate the prevalence of two other stereotypical characteristics
of patent trolls: a propensity for asserting high-tech patents and a tendency
to lose when forced to adjudicate their infringement claims on the merits.
In essence, this analysis further measures the extent to which NPEs take
advantage of the tail end of the patent term. Product lifecycles in the hightech industry are notoriously short. Computing power, after all, doubles
roughly every two years.114 Thus, high-tech patents are the most likely to be
grossly out of date—technologically speaking—when asserted nearly two
decades after their filing dates. Additionally, the success rate of NPEs in
infringement allegations suggests that they are relying on strained claim
interpretations to stretch aging patents to cover more advanced technology.115
Table 8 below provides a technology-by-technology breakdown of patent
litigation filed by product-producing companies and NPEs; the Table also
measures changes in the division of patented technology over time. This
data reveals that high-tech patents play a disproportionate role in NPE
litigation and in late-term litigation generally. Overall, about 65% of NPEasserted patents cover computer- or electronics-related inventions, and almost
40% cover the narrower category of software-related inventions.116 By
contrast, just over 40% of product company–asserted patents cover hightech inventions and just 25% cover software-related subject matter.117 The
114 This observation, which has held true for decades, is known as “Moore’s law.” See Gordon
E. Moore, Progress in Digital Integrated Electronics, Int’l Electron Devices Meeting, IEEE (1975)
(predicting that computing power will double approximately every two years), reprinted in SSCS:
IEEE SOLID-STATE CIRCUITS SOC’Y NEWS, Sept. 2006, at 36, 37.
115 See infra Table 9.
116 Michael Risch, who used PTO classification numbers to define high-tech subject matter,
found that 40% of patents asserted by the ten most litigious NPEs were high-tech inventions.
Risch, supra note 1, at 477; see also id. (finding that the majority of high-tech patents in his study
were software patents (84 of 138 total)). Bessen et al. found that 62% of patents litigated by NPEs
between 1990 and 2010 were “software patents” and 75% covered “computer and communications
technology.” Bessen et al., supra note 102, at 12.
117 The difference between product-producing companies’ and NPEs’ enforcement of software patents is statistically significant per patent ( p = 0.008), per suit ( p < 0.001), and per
assertion ( p < 0.001). The difference between product-producing companies’ and NPEs’ rates of
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share of high-tech litigation by product companies is roughly the same
whether measured by patent, by suit, or by assertion. However, for NPEs,
high-tech litigation accounts for a substantially higher 82% of suits and 80%
of assertions.118
Among patents asserted in the final three years of their terms, the proportion of high tech–subject matter patents increases, surprisingly, for all
patentees. That is, high-tech patents account for an outsized percentage of
patent claims filed in that period by both product-producing companies and
NPEs.119 In fact, in the final three years of the patent term, the high-tech
gap between NPEs and product-producing companies narrows considerably.
This pattern exists not because the high-tech share of NPE litigation
shrinks (it grows to 88% of assertions120), but rather because the high-tech
share of product-company litigation skyrockets to over 71% of assertions.121

enforcement of other high-tech patents is statistically significant at a 90% level per patent ( p =
0.057), not significant per suit, and significant at a 95% level per assertion ( p = 0.029).
118 As shown in Table 8, the difference between product-producing companies’ and NPEs’
share of all four technology categories is only statistically significant on a per-assertion basis
(software p < 0.001; other high-tech p = 0.029; medical device p < 0.001; biotech-pharmaceutical
p < 0.001).
119 The prevalence of high-tech litigation in the final few years of the patent term, together
with the large share of NPE litigation involving high-tech products, could suggest that my
findings on litigation timing merely reflect the fact that high-tech patents tend to be litigated late
in the patent term. Further analysis of my data directly contradicts this hypothesis, however.
Product-producing companies asserting high-tech patents litigate those patents far earlier than
their NPE counterparts. Among all high-tech patents, I find that product-producing companies
begin enforcement with an average of 11.5 years of patent term remaining, while NPEs begin with
just 8.3 years remaining. This difference is statistically significant ( p < 0.001). Among the same
group of patents, product-producing companies finish enforcement with an average of 9.0 years of
term remaining, while NPEs conclude their enforcement efforts with just 3.4 years of term left.
Again, this difference is highly statistically significant ( p < 0.001). I find similar results looking at
software patents only. On average, product-producing companies begin enforcement with 11.8
years of term remaining and finish with 8.9 years of term left. On average, NPEs begin with 8.6
years of term remaining and conclude just 2.9 years before expiration. These differences are both
statistically significant ( p < 0.001 for both).
120 This growth is statistically significant among software claims ( p < 0.001) and among other
high-tech claims ( p = 0.009).
121 While growth in the number of product-company software claims is not statistically significant, growth in the number of other high-tech claims is highly significant ( p < 0.001). Growth
in the number of product-company high-tech suits is also significant ( p < 0.001). Growth in the
number of high-tech patents enforced by product companies is, however, not significant.
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Table 8: Technology Areas122
Patent
Overall123
% software
% other high-tech
% medical device
% bio-pharma
Litig. complete, more
than 3 yrs. from exp’n126
% software
% other high-tech
% medical device
% bio-pharma
Litig. ongoing, less
than 3 yrs. from exp’n
% software
% other high-tech
% medical device
% bio-pharma

Prod. Co.
Suit Assertion

Patent

NPE
Suit

Assertion

25.5
16.2
8.4124
5.4

21.7
15.5
7.0
6.8

22.2
16.2
10.6
6.0

39.8*
25.0**
12.5125
0*

65.6*
16.3
4.5
0*

60.6*
20.0*
5.5*
0*

24.4
15.2
8.1
4.4

21.0
12.9
7.1
5.0

21.6
11.5
11.7
4.6

32.5
22.5
10.0
0

62.1
15.9
5.5
0

52.3
15.9
4.8
0

34.2
23.7
10.5
13.2*

26.7
33.3*
6.7
18.3*

25.8
45.4*
3.8*
15.2*

45.8
27.1
14.6127
0

69.2
16.8
3.5
0

65.3*
22.5*
5.8
0

*p < 0.05; **p < 0.10

Finally, Table 9 displays litigation outcomes for product companies and
NPEs, including how these outcomes change with patent age.128 The results
suggest that NPEs lose at a higher rate than product-producing companies
when their infringement claims are adjudicated and, again, that this disparity
is even larger among patents litigated late in the term. The small number of
122
123
124

See Timing Dataset.
p-values compare product company versus NPE patents, suits, and assertions.
Of the 28 product-company patents that cover medical devices, 10 (which collectively
account for 11 suits and 15 assertions out of 35 and 102 total, respectively, involving medical
devices), are also high-tech–related. Five of those 10, which account for 5 suits and 6 assertions,
are software-related. See Timing Dataset.
125 Of 11 total NPE patents that cover medical devices, 4 (which collectively account for 7
suits and 24 assertions out of 15 and 58 total, respectively, involving medical devices), are also
high-tech–related. One of those 4, which accounts for 3 suits and 6 assertions, is software related.
See Timing Dataset.
126 p-values comparing patents, suits, and assertions resolved more than and less than three
years before expiration.
127 Two medical device patents, which collectively account for three suits and ten assertions,
are also high-tech related. See Timing Dataset.
128 The data in Table 9 reports whether each patent has ever been found infringed, not infringed, or invalid at the district court level before appeal. Data on appeals is not considered in
this study. See supra note 67.
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patents adjudicated, however, renders the detection of a statistically significant difference difficult. Overall, more than 55% of adjudicated NPE patents
were found by a judge or jury not to be infringed, compared with just under
30% of adjudicated product company patents.129 Similarly, productproducing companies proved infringement of almost half their adjudicated
patents, while NPEs proved infringement of less than a quarter.130 Moreover, the difference between product-producing companies’ and NPEs’
success at proving infringement grows with time, though not because NPEs
become worse (to a statistically significant degree, anyway). Rather, productproducing companies become more successful. Among adjudicated patents
litigated in the final three years of the patent term, product-producing
companies proved infringement nearly 67% of the time,131 while NPEs fail
to prove infringement or establish validity over 80% of the time.132

129
130

The difference is significant at the 95% level ( p = 0.038).
This difference is significant at a 90% level ( p = 0.053). Also, note that I do not count
default judgments as “adjudications.”
131 This increase is not statistically significant ( p = 0.145).
132 One NPE-asserted patent was found both invalid and not infringed. One possible confounding factor here is that, over time, it has become easier for accused infringers to locate prior
art that restricts patentees’ ability to advance broad claim interpretations. See, e.g., F. Russell
Denton, Plumb Lines Instead of a Wrecking Ball: A Model for Recalibrating Patent Scope, 16 J. INTELL.
PROP. L. 1, 24 (2008) (noting that prior art searching “has become easier because of advances in
search technology, online bandwidth, a growth industry in database searches . . . , and the
appearance of free searchable PTO online databases, not to mention other public online databases”); see also Allison & Lemley, supra note 41, at 138 (discussing how computer searching may
have improved patent examiners’ ability to locate prior art). Note, however, that the invalidity
rates reported in Table 9 do not appear to support this hypothesis.
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Table 9: Litigation Outcomes133

Overall
Adjudicated
Infringed
Noninfringed
Invalid
*p-values > 0.10 omitted
Litig. complete, more than
3 yrs. from exp’n137
Adjudicated
Infringed
Noninfringed
Invalid
Litig. ongoing, less than
3 yrs. from exp’n
Adjudicated
Infringed
Noninfringed
Invalid

Prod. Co.

NPE

p-value*

19.5%
47.7%134
29.2%
30.8%135

21.6%
22.2%
55.5%
27.8%136

-0.053
0.038
--

18.0%
43.4%
32.1%
28.3%

17.5%
28.6%
57.1%
28.6%

31.6%
66.7%
16.7%
41.7%

22.9%
18.2%
54.5%
27.3%

III. IMPLICATIONS
The results presented above demonstrate that NPEs play a more important role in the patent system than previously recognized, a role that
becomes fully apparent only when accounting for the age of the patents
they litigate. In short, while NPEs do not assert the majority of litigated
patents or even file the majority of patent suits, they play a dominant role
in patent litigation in the waning years of the patent term.

133
134

See Timing Dataset.
One product company–asserted patent was found both infringed and not infringed in
different cases. See id.
135 Four product company–asserted patents were adjudicated before being invalidated. Two
were found infringed, and two were found not infringed. See id.
136 One NPE-asserted patent was found both not infringed and invalid. See id.
137 The only change that is statistically significant at a confidence level of 90% or greater is
the increase in the percentage of product company patents adjudicated, which is statistically
significant at the 95% level (p = 0.046).
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A. NPEs Are Mostly Not Technology Disseminators;
Product-Producing Companies Are Not Entirely Blameless
What does this fact mean for our opinion of NPEs? For one, it serves as
one more nail in the coffin containing NPEs’ claims that they play a “central role in helping commercial entities obtain the rights to use valuable
technologies that produce new and beneficial products.”138 NPEs asserting
patents filed by others roughly two decades ago cannot credibly claim that
they are championing the rights of their accused infringers’ contemporaneous
competitors. Similarly, with the notable exception of individual inventors,
NPEs asserting their own patents are by no means rushing to the courthouse to vindicate their own rights soon after their patents issue. Instead,
NPEs appear to be engaged in classic troll-like behavior: suing the better
part of a well-established industry for infringement of an aging patent,
generally one covering software or high-tech subject matter, and consistently
losing those claims when pushed to prove their infringement allegations.139
According to the data discussed above, NPEs’ claims that they are vindicators of hard-fought patent rights become even less plausible after
considering the breakdown of NPE-asserted patents by technology and
industry. Almost 65% of NPE patents cover high-tech subject matter in
general, and about 40% are software related. Worse still, more than 80% of
NPE-filed suits assert high-tech patents generally, and more than 65% have
software-related claims. None cover pharmaceutical or biotech inventions,
and less than 13% cover medical devices.140 Among NPE patents asserted in
suits ongoing within three years of their expiration, almost 46% are software
patents and more than 72% are high-tech related. And, on a per-assertion
basis, almost 88% of NPE patent enforcement in the final three years of the

138
139

Kacedon et al., supra note 18.
The breadth and age of NPE patents could alternatively (and more generously) suggest
that these patents are far from stale and, instead, cover inventions so ahead of their time that it is
not until years later that commercial applications (and thus products) emerge. A growing body of
scholarship, however, strongly suggests that “pioneering inventions” of this sort are quite rare. See
Mark A. Lemley, The Myth of the Sole Inventor, 110 MICH. L. REV. 709, 713, 715-33 (2012) (offering
historical evidence to show that the vast majority of the so-called “pioneering inventions” of the
past two centuries, including the steam engine, the telephone, and the lightbulb, were independently and contemporaneously invented by multiple inventors); Brian J. Love, Interring the
Pioneer Invention Doctrine, 90 N.C. L. REV. 379, 429-35 (2012) (listing a large number of pioneering inventions that were independently and contemporaneously invented); Samson Vermont,
Independent Invention as a Defense to Patent Infringement, 105 MICH. L. REV. 475, 478-79 (2006)
(listing a large number of inventions invented contemporaneously, and noting that “[s]ome
historians and philosophers of science believe convergence is the rule rather than the exception”).
140 Many of these medical device patents, in turn, have a significant high-tech or software
component. See supra notes 124-25 & 127 (describing the overlap in these categories).
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patent term is high-tech focused. In essence, where innovation is rapid and
cheap, NPEs dominate; where innovation is slow and expensive, NPEs are
nowhere to be found.
Interestingly, a significant portion of product-company litigation ongoing in the waning years of the patent term fares little better. Among
product-company patents in litigation within three years of expiration, a
large percentage (about 58%) cover high-tech inventions. On a per-assertion
basis, this rate jumps to over 71%. Perhaps not surprisingly, upon closer
examination, many of the suits responsible for this jump bear the hallmarks
of troll litigation even though they are brought by product-producing
patentees. Several are suits filed by failing companies hoping to use patent
litigation to keep their doors open just a little while longer. Now-bankrupt
film and camera maker Kodak,141 for example, sued virtually every
smartphone manufacturer, seeking $1 billion in damages for infringement of
old software patents covering image capture, compression, and preview
technology.142 A struggling Encyclopaedia Britannica143 launched a similar
patent offensive against the GPS-mapping industry for infringement of its

141 Kodak filed for bankruptcy in January 2012. Michael J. De La Merced, Eastman Kodak
Files for Bankruptcy, N.Y. TIMES DEALBOOK ( Jan. 19, 2012, 1:12 AM), http://dealbook.nytimes.
com/2012/01/19/eastman-kodak-files-for-bankruptcy.
142 See Rich Duprey, The Worst Stocks of 2010: Eastman Kodak, MOTLEY FOOL ( Jan. 21, 2010),
http://www.fool.com/investing/general/2010/01/21/the-worst-stocks-for-2010-eastman-kodak.aspx
(noting that Kodak “sees its future as being little more than a patent troll” because “[a]s its film
business collapsed, Kodak was left with few options other than to turn to its patent portfolio to
eke out a living”); Jason Mick, Kodak Demands Over $1B USD from Apple, RIM for Alleged
Infringement, DAILY TECH (Mar. 25, 2011, 2:17 PM), http://www.dailytech.com/Kodak+Demands+
Over+1B+USD+From+Apple+RIM+for+Alleged+Infringement/article21228.htm (noting that between
1993 and 2007 Kodak “went on a patent binge, spending on patents and acquiring small startups”
and “beef[ed] up its digital imaging IP”); see also Complaint and Jury Claim at 2-7, Eastman
Kodak Co. v. Apple Inc., No. 6:10-CV-06022-MAT-JWF (W.D.N.Y. Jan. 14, 2010) (filing an
action against Apple for allegedly infringing multiple Kodak patents by selling a number of
products including iPhones, MacBooks, and iPods); Complaint at 2-3, 5, Research in Motion, Ltd.
v. Eastman Kodak Co., No. 3:08-CV-02075-K (N.D. Tex. Nov. 20, 2008) (stating that Kodak had
previously sent a letter to Research in Motion alleging infringement of three patents and
“demanded exorbitant royalties from RIM for this alleged infringement,” and filing an action for a
declaratory judgment against Kodak). Kodak recently put more than 1000 patents up for sale with
the possibility of generating more than $3 billion in revenues. Chris Burritt, Kodak CEO Says a
‘Large Number’ of Buyers Evaluating Patents for Purchase, BLOOMBERG (Aug. 30, 2011, 4:27 PM),
http://www.bloomberg.com/news/2011-08-30/kodak-says-large-number-of-buyers-evaluating-itspatents-1-.html.
143 Encyclopaedia Britannica announced in March 2012 that its 2010 print edition would be
its last. Julie Bosman, After 244 Years, Encyclopaedia Britannica Stops the Presses, N.Y. TIMES MEDIA
DECODER (Mar. 13, 2012, 5:54 PM), http://mediadecoder.blogs.nytimes.com/2012/03/13/after-244years-encyclopaedia-britannica-stops-the-presses.
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notoriously broad software patent.144 Other suits were filed by productproducing companies that acquired patent rights purely for litigation
purposes. Gemstar-TV Guide,145 for example, acquired the right to assert,
among others, patents owned by former satellite-TV company SuperGuide146 in a long-running patent battle with the DVR industry.147 Other
product-producing companies suddenly asserted aging high-tech patents that
had changed hands several times or asserted these patents against an entire
industry.148 These suits, the likes of which do not occur earlier in the patent

144 See Complaint for Patent Infringement and Jury Demand at 5, 8-9, Encyc. Britannica,
Inc. v. Alpine Elecs. of Am., Inc., No. 1:05-CV-00359-LY (W.D. Tex. Sept. 30, 2008) (alleging
that Garmin and other defendants infringed a patent on a “novel computer search system for
retrieving various types of information”); Encyc. Britannica, Inc. v. Magellan Navig’n, Inc., 512 F.
Supp. 2d 1169, 1171-72 (W.D. Wis. 2007) (describing Encyclopaedia Britannica’s suit against six
parties, including Magellan Navigation, for infringing the search system); Mike Masnick, It
Appears that the Encyclopedia Britannica Entry on Shaking Down GPS Providers with a Bogus Patent
Needs Updating, TECHDIRT ( June 28, 2010, 11:56 AM), http://www.techdirt.com/articles/20100625/
2351149966.shtml (describing the history of the search system patent at issue in Encyclopaedia
Britannica’s lawsuits against GPS companies).
145 Gemstar merged with TV Guide, Inc. in July 2000. U.S. Settles Antitrust Case Against
Gemstar, N.Y. TIMES, Feb. 7, 2003, at C3. Macrovision (now Rovi Corp.) acquired Gemstar-TV
Guide in May 2008. Rafat Ali, TVGuide No More: Macrovision’s Acquisition of Gemstar Complete; To
Be Called Macrovision Solutions, WASH. POST (May 2, 2008), http://www.washingtonpost.com/wpdyn/content/article/2008/05/02/AR2008050202391.html.
146 See SuperGuide Corp. v. DirecTV Enters., Inc., 358 F.3d 870, 873 (Fed. Cir. 2004) (noting
that Gemstar obtained an exclusive license from SuperGuide on three patents that would
subsequently become the subject of litigation).
147 See, e.g., id. at 873-74 (noting that Gemstar was impleaded as a third-party defendant to
SuperGuide’s infringement suit, and that Gemstar alleged that defendant EchoStar infringed each
of the three asserted patents); Certain Set-Top Boxes and Components Thereof, Inv. No. 337-TA454, USITC Pub. 3564 (Nov. 2002) (Final) (discussing an investigation into a patentinfringement case brought by Gemstar against several companies, including Pioneer Corp. and
EchoStar Communications Corp.); see also 2 RICHARD RAYSMAN ET AL., EMERGING TECHNOLOGIES AND THE LAW § 8.05[5] (2003) (describing how Gemstar “expanded its portfolio of
patents through various licensing arrangements” and began to enforce those rights aggressively in
an effort to gain “a controlling position in the market for interactive program guides,” a market
which matured to include technology far more advanced than what was envisioned in Gemstar’s
“aging patent portfolio”).
148 My sample included a number of high-tech patents originally assigned to AT&T Bell
Labs that changed hands after the company’s spin-off to Lucent and eventually found their way
into court in the mid-to-late 2000s. See, e.g., Timing Dataset, U.S. Patent No. 5,298,047; id., U.S.
Patent No. 5,287,427; id., U.S. Patent No. 5,243,229; id., U.S. Patent No. 5,235,659. Another hightech patent, owned by Anvik Corp., was asserted in twelve suits against thirty-five defendants
(essentially every flat-panel display/TV manufacturer) in the late 2000s. See Timing Dataset, U.S.
Patent No. 5,285,236. One other software patent changed hands in 2009 and was asserted for the
first time that same year in three suits against six defendants. See Timing Dataset, U.S. Patent No.
5,233,629.
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term, support one point that NPEs have made for years: product-producing
companies are just as capable of filing suspect patent suits as NPEs are.149
B. Patent Term Reform
Together, the suspect quality of litigation brought by NPEs and productproducing companies late in the patent term suggests that Congress might
enhance innovation by shortening the patent term by three years or even
longer. In these final years of the patent term, product-producing companies seem to have all but abandoned enforcement of patents for products
from years earlier. Many of those product-producing companies still
litigating aging patents appear to have the same motives and characteristics
attributed to their much-maligned troll adversaries—and presumably
impose the same social costs.150 All other things being equal,151 a three-year
term reduction would impact almost 50% of all NPE suits,152 while affecting
roughly 13% of product-company suits.153 On a per-assertion basis, a threeyear term reduction could cut short154 more than 26% of all NPE assertions
and eliminate another 35% of NPE assertions,155 while cutting short less

149 See Merges, supra note 6, at 1610-11 (“[T]ypically, it is not specific entities, but rather
specific tactics or practices that are most relevant . . . . Trolling, to put it simply, is a matter of
behavior rather than status.”).
150 In a study of accused infringers’ stock prices following a lawsuit, Bessen et al. found that
the average NPE suit cost accused infringers $122 million. Bessen et al., supra note 102, at 16.
Between 1990 and 2010, the aggregate wealth lost to NPE suits was approximately $500 billion. Id.
at 17. In a subsequent article, Bessen and Meurer estimate that in 2011, firms spent approximately
$29 billion defending against NPE infringement claims. James Bessen & Michael J. Meurer, The
Direct Costs from NPE Disputes 19 (Bos. Univ. Sch. of Law, Working Paper No. 12-34, 2012),
available at http://ssrn.com/abstract=2091210.
151 Of course, all things might not remain equal following patent term reform. See infra Section
III.C.
152 Of 288 total NPE suits, 72 were filed in the last three years of the patent-in-suit’s term
and another 71 were resolved within the same time period though filed a bit earlier. See Timing
Dataset.
153 Of 456 total product company suits, 31 were filed in the last three years of the patent-insuit’s term and another 29 were resolved within the same time period though filed a bit earlier. Id.
154 By “cut short,” I mean that the patent-in-suit would expire during litigation. Patentees
could continue to litigate for past infringement, but they would be precluded from receiving an
injunction or ongoing royalty after winning summary judgment or at trial because the alleged
infringer’s future activities would no longer potentially infringe.
155 Of 1069 total NPE assertions, 376 were brought within three years of the patent-in-suit’s
expiration and another 278 were resolved during the same period but filed earlier. See Timing
Dataset.
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than 8% of product company assertions and eliminating less than 6% of
product company assertions.156
Though the majority of affected patents would merely expire during
their final assertions (rather than before those are filed), there is good
reason to believe the balance of power would still shift dramatically in these
cases. Without live patents, patentees cannot seek permanent injunctions157
or ongoing royalties158 even if they ultimately win their infringement
claims. The possibility of both remedies gives patentees leverage to hold up
accused infringers for outsized settlements.159
Furthermore, there is good reason to believe that product-producing
companies could easily be, and as a practical matter would be, insulated
from a term reduction to a degree greater than the statistics above suggest.
For one, any legislation reforming the patent term could exclude practicing
patentees in the biotech, pharmaceutical, and medical-device industries,
which collectively assert about 24% of product-company patents litigated in
the final three years of the patent term. Unlike their high-tech counterparts,
these patents cover well-defined and well-known products approved by the
Food and Drug Administration (FDA), and are frequently litigated at the
very end of the patent term against generic manufacturers seeking a leg up
in the production of low-cost alternatives to successful name brand drugs,
diagnostics, and devices. Would a term reduction harm incentives to
produce more of these life-saving inventions? Perhaps not. Pharmaceutical
companies are exceedingly skillful at extending their market power over
drugs by filing newer patents covering related subject matter—a process
156 Of 964 total product company claims, 56 were brought within 3 years of the patent-insuit’s expiration and another 76 were resolved during the same period but filed earlier. See Timing
Dataset.
157 After eBay, Inc. v. MercExchange, L.L.C., the possibility that a successful NPE will receive
injunctive relief is diminished, but certainly nonzero. See 547 U.S. 388, 393-94 (2006) (rejecting
the Federal Circuit’s “‘general rule’ . . . that a permanent injunction will issue once infringement
and validity have been adjudged”), rev’g MercExchange L.L.C. v. eBay, 401 F.3d 1323 (Fed. Cir.
2005); see also Lily Lim & Sarah E. Craven, Injunctions Enjoined; Remedies Restructured, 25 SANTA
CLARA COMPUTER & HIGH TECH. L.J. 787, 798 (2009) (noting that, post-eBay, “a patentee who
directly competes in the marketplace with the infringing party gets an injunction 79.6% of the
time, while an NPE’s chance of an injunction falls precipitously to 33.3%”).
158 See Mark A. Lemley, The Ongoing Confusion Over Ongoing Royalties, 76 MO. L. REV. 695,
702-03 (2011) (noting, for example, that some courts have granted treble ongoing royalties on the
theory that adjudicated infringers who continue to sell the infringing products are “willful”
infringers).
159 See Lemley & Shapiro, supra note 5, at 2008 (explaining that a threat of injunction can
“enable a patent holder to negotiate a settlement for an amount of money significantly exceeding
the amount that the patent holder could expect to earn in damages based on reasonable royalties . . . [because of] the cost to the defendant of switching technologies [in their products]
midstream . . . .”).
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known as “evergreening.”160 In fact, for this very reason, a term reduction
would impact product-producing companies far less than one might anticipate because, unlike NPEs, a product company can always file new patents
covering improved, next-generation versions of its products. That is, while
a product company with an expired patent likely has recourse to additional
similar patents, an NPE with an expired patent is out of luck and must
purchase a replacement.
In any event, it would be logistically simple to exclude medical, biotech,
and pharmaceutical patents from any legislation curtailing late-term patent
rights because the PTO already has experience singling out such inventions
for special treatment. For example, current law already permits term
extensions for patents covering products that require FDA approval.161
These existing provisions could be reformed to lower the bar for term
extensions or simply to exclude patents owned by the makers of FDAapproved medicines, diagnostics, or devices from any term reduction
reforms.162
Excluding cases and assertions brought by pharmaceutical, biotech, and
medical device firms, a modified three-year term reduction would impact
less than 10% of all product-company suits and roughly 11% of assertions.163
Taking product-company “trolling” into account would reduce this percentage even further. Additionally excluding those suits and assertions brought

160 See Rebecca S. Eisenberg, The Role of the FDA in Innovation Policy, 13 MICH. TELECOMM.
& TECH. L. REV. 345, 354 (2007) (providing examples of evergreening, such as “patents on
‘metabolites’ (i.e., the products into which drugs are transformed in a patient’s body); patents on
intermediate products used in producing drugs; patents on new uses for drugs; and patents on new
formulations or preparations”); see also Tamsen Valoir, Six Methods of Preserving Market Exclusivity,
18 INTELL. PROP. & TECH. L.J. 12, 14 (2006) (“[A] generic class of drug molecules might be
claimed in an initial patent application, but specific members can be claimed in later unrelated
applications as the pharmaceutical data for such members becomes available. Because the followon patent does not claim priority to the original application, its term will run from the new filing
date.”).
161 See 35 U.S.C. § 156 (2006) (establishing that a product patent can receive a term extension if, among other conditions, the product has “been subject to a regulatory review period [by the
FDA] before its commercial marketing or use”). Thus, while it may be exceedingly difficult, if not
impossible, to draw bright lines between many other industries, it appears to be relatively simple
to separate this cohort of patents. None of the pharmaceutical, biotech, or medical device patents
in my sample received a term extension. For a list of extended patents, see Patent Term Extensions,
U.S. PATENT AND TRADEMARK OFFICE (Apr. 4, 2012, 3:57 PM), http://www.uspto.gov/patents/
resources/terms/156.jsp.
162 Requiring the commercialization of a product would exclude NPE-asserted medical
device patents—more than 12% of all NPE patents, see Timing Dataset—from the benefit of any
such reform.
163 Collectively, these patentees filed fifteen suits, accounting for twenty-five assertions,
resolved within three years of the patent-in-suit’s expiration. See Timing Dataset.
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by the troll-like product-producing companies mentioned above, a threeyear reduction in the patent term would disrupt roughly 5.5% of “legitimate” product company patent suits and assertions.164
C. Limitations
One thing this study cannot predict, however, is how patentees would
adjust their litigation timing in response to a term reduction. Though, as
discussed above, patents often do not reach NPEs for years, a substantial
component of NPE litigation delay is simply that: delay. On average, NPEs
wait about 3.1 years to file suit after obtaining a patent.165 Is it possible,
then, that NPEs could dodge a term reduction simply by filing suit several
years earlier than they presently do? The answer is almost certainly “no” for
the vast majority of NPEs, which overwhelmingly target successful hightech products.166 NPEs cannot file suit before targeted products hit the
market and generally will not do so before those products go on to become
popular with consumers. Thus, because the lifecycles of very few high-tech
products exceed three years, as a practical matter very few NPE claims can
be expedited beyond three years.167 Put simply, most of the products that
NPEs target today did not exist three years ago. In any event, requiring
NPEs to race to the courthouse would, by itself, produce significant benefits. It would, for example, force some NPEs to litigate before allegedly
infringing products are incorporated into technology standards or costly
fixed investments,168 thus weakening NPEs’ hold-up power.169 Nonetheless,
the results reported above must be discounted to some extent by uncertainty
about NPEs’ ability to sue at an earlier time.
Further, while I have used the terms “enforcement” and “litigation” interchangeably above, the results of this study are only as strong as the degree
164 Collectively, these patentees filed twenty suits, accounting for fifty-three assertions, resolved within three years of the patent-in-suit’s expiration. See Timing Dataset.
165 See supra Table 5.
166 See Mark A. Lemley, Should Patent Infringement Require Proof of Copying?, 105 MICH. L.
REV. 1525, 1526 (2007) (noting that patent trolls “assert patents against successful companies that
independently develop and manufacture technology without knowledge of those patents”);
Shrestha, supra note 1, at 140 (noting that NPEs tend to sue “manufacturers of successful
products”).
167 See Moore, supra note 114, at 37 (observing that computing power advances at a rapid rate,
doubling every two years).
168 Cf. Robert P. Merges & Jeffrey M. Kuhn, An Estoppel Doctrine for Patented Standards, 97
CALIF. L. REV. 1, 13-15 (2009) (describing the “snake-in-the-grass strategy” whereby patentees
hide “the existence of patents in order to assert them against industry members who become
locked into a standard”).
169 See supra note 159 and accompanying text.
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to which the temporal bounds of litigation match those of all patent enforcement. Because patent licenses negotiated outside the court system are
almost always kept confidential, it is virtually impossible to measure the
total level of patent enforcement that product-producing companies undertake after ceasing litigation, that NPEs undertake before filing suit, and that
all patentees undertake with patents that are never asserted in court.
While the amount of each type of nonlitigation patent enforcement is
certainly nonzero, there is good reason to believe that this source of uncertainty is not fatal to studies of this kind. First, while some NPEs do
license their patents without litigation,170 they face at least one very strong
incentive not to do so: the importance of forum selection. If litigation
appears imminent, a threatened product company can and generally will file
a declaratory judgment action in a favorable jurisdiction to prevent the
impending suit from proceeding in a patentee-friendly district.171 What it
almost certainly will not do is closely review unsolicited license offers from
small NPEs.172 Accordingly, it seems reasonable to assume that the most
sophisticated NPEs, especially those who are repeat players, adopt a
litigate-first strategy, and that sophisticated product-producing companies
do, too, when confronted with serious NPE infringement claims.
Unlike NPEs, however, product-producing companies more frequently
resolve patent disputes without litigation. One reason is that patent litigation is especially costly for accused infringers. Thus, unlike NPEs, which
cannot be counter-sued for patent infringement, product-producing companies are exposed to potential patent infringement claims, and must therefore be careful about suing other product-producing companies.173 In
170 See Michael J. Meurer, Controlling Opportunistic and Anti-competitive Intellectual Property
Litigation, 44 B.C. L. REV. 509, 517 (2003) (noting that E-Data, a company that “owns a patent
which arguably covers financial transactions on the Internet,” reportedly sent demand letters to
75,000 alleged infringers before suing forty-one companies for patent infringement).
171 See Kimberly A. Moore, Forum Shopping in Patent Cases: Does Geographic Choice Affect Innovation?, 79 N.C. L. REV. 889, 921 (2001) (“When the patent holder selects the forum, the patent
holder wins 58% of the claims. When the accused infringer brings a declaratory judgment action
and thereby chooses the forum, the patent holder win rate drops to 44%.”). But cf. Chester S.
Chuang, Offensive Venue: The Curious Use of Declaratory Judgment to Forum Shop in Patent Litigation,
80 GEO. WASH. L. REV. 1065, 1084 (2012) (finding a significantly higher transfer rate for
declaratory judgment cases relative to non–declaratory judgment cases, and concluding that
“accused infringers are often unable to secure their desired forum via declaratory judgment”).
172 See Mark A. Lemley, Ignoring Patents, 2008 MICH. ST. L. REV. 19, 21-22 (2008) (noting
that companies generally ignore patents in all stages of product development, including research
and design, patent filing, product launches, and even after the receipt of cease-and-desist letters
from patent owners).
173 See Christopher A. Cotropia, The Individual Inventor Motif in the Age of the Patent Troll, 12
YALE J.L. & TECH. 52, 55 (2009) (“If a defendant is sued by [a] patent troll[], the alleged
infringers do not have the usual retaliatory mechanism—the ability to assert their own patents in
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addition to litigation expenses, competitors face other strong incentives not
to challenge each other’s patents. For example, they bear the cost of the
challenge but share the benefit of invalidation with the rest of the industry,
including competitors.174 All of these factors suggest that, among productproducing companies, patent litigation is generally a last resort used against
especially recalcitrant competitors. Finally, at least among productproducing companies that actively license their patent portfolios, it is
standard practice to license relatively large pools of patents, rather than a
select few.175 It is unlikely that removing the oldest patents from a large
pool would substantially reduce the pool’s value to a competitor looking to
clear a path to commercialize a new, cutting edge product. Accordingly,
only very little, if any, of the value of such a license should be attributed to
the most aged patents in the pool.176
Finally, some in the patent community perceive an increase in the share
of patent litigation attributable to NPEs in recent years. If this trend does
exist, my findings on late-term NPE litigation could be inflated by the fact
that fewer NPEs existed during the 1990s and early 2000s when, perhaps,
they might have enforced younger patents. One oft-repeated narrative
explains the NPE business model as a recent phenomenon popularized after
the burst of the dot-com bubble.177 Recent scholarship, however, casts
serious doubt on this conventional wisdom. Michael Risch reports, for
example, that large-scale NPE operations date back to at least the mid-1980s,
return—because the patent troll does not sell any products or offer any services which could
infringe.”); Crane, supra note 29, at 286 (“[T]rolls and commercializers supposedly have asymmetrical incentives, since trolls are only interested in exacting payments whereas commercializers
often resolve infringement disputes with other commercializers through cross-licensing arrangements.”).
174 See Joseph Farrell & Robert P. Merges, Incentives to Challenge and Defend Patents: Why
Litigation Won’t Reliably Fix Patent Office Errors and Why Administrative Patent Review Might Help,
19 BERKELEY TECH. L.J. 943, 958 (2004) (“[A] challenger bears the cost of litigation but its rivals
and downstream buyers will capture almost all the benefits of successful challenge . . . .”).
175 See Gideon Parchomovsky & R. Polk Wagner, Patent Portfolios, 154 U. PA. L. REV. 1, 8-9
(2005) (“While large firms provide perhaps the most compelling example of patent portfolios in
practice . . . we also find real world case studies of patenting behavior consistent with our theory
among startups and acquisition-centric firms. Indeed, the rise of patent portfolios in the business
community has become so significant that portfolios have become the credo of firm value in the
modern innovation environment.”).
176 See id. at 77 (“We find that for patents, the whole is greater than the sum of its parts. The
true value of patents lies not in their individual worth, but in their aggregation into a collection of
related patents—a patent portfolio.”); cf. Mark A. Lemley, Software Patents and the Return of
Functional Claiming 35 (Stanford Pub. Law, Working Paper No. 2117302, 2012), available at
http://ssrn.com/abstract=2117302 (“Smartphone companies, for instance, would likely take little
solace in being told that they need only clear rights for 25,000 essential patents, not 250,000.”).
177 See, e.g., John A. Marlott, NPEs and Pre-Litigation Considerations, 1020 PLI/Pat 453, 457 (2010).
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were very active in the 1990s, and, in some instances, markedly decreased
their activity in the 2000s.178 Other scholars have documented the existence
of NPEs throughout U.S. history.179 Nonetheless, there appears to be at
least a kernel of truth to the conventional wisdom that NPEs ascended from
the ashes of the 2000–2001 tech stock crash. Two recent studies of patent
suits filed post-2000 suggest that the percentage of patent suits brought by
NPEs has, on net, increased over the last decade.180 Pending additional,
broader studies on this topic, my findings should be interpreted with the
caveat that they reflect some degree of selection bias caused by an increase
over time in the percentage of litigation activity attributable to NPEs.181
D. Maintenance Fee Reform
Is the potential disruption of roughly 5.5% of product-company assertions (54 claims in this study) worth trading for the potential elimination of
more than 35% of NPE claims and the dilution of another 26% of claims
(654 total claims in this study)? Perhaps not, given the limitations discussed
178 See Risch, supra note 1, at 475 (reporting that, of the ten most litigious NPEs since 2003,
two filed their first suit in 1986, nine filed their first suit before 2000, and three ceased filing suits
during the 2000s).
179 See Merges, supra note 6, at 1592-96 (summarizing the long history of patent-related
“rent-seeking” in the United States, especially in the agricultural industry in the 1860s and 1870s,
in the railroad industry during the next few decades, and in the automobile industry after the turn
of the century); see also Colleen V. Chien, Reforming Software Patents, 50 HOUSTON L. REV. 325,
335-36 (2012) (recounting similar historical examples of patent trolling).
180 See Chien, supra note 3, at 1604 fig.2 & n.168 (finding, in a study of 2300 high-tech patent
suits filed between 2000 and 2008, that NPEs filed 10% of all suits between 2000 and 2001, 16%
between 2002 and 2003, 16% between 2004 and 2005, and 20% between 2006 and 2008); Jeruss et
al., supra note 24, at 378 (finding, in a study of 100 patent suits filed each year from 2007 to 2011,
that the percentage asserted by “monetizers,” or NPEs, was roughly 22% in 2007, 27% in 2008, 33%
in 2009, 30% in 2010, and 40% in 2011). Neither study makes any findings with respect to the ages
of asserted patents.
181 The availability of inter partes reexamination is another possible confounding influence.
Potential infringers have the option to request the inter partes reexamination of patents filed on or
after November 29, 1999. 37 C.F.R. § 1.913 (2011); see also Leahy-Smith America Invents Act,
Pub. L. No. 112-29, § 6, 125 Stat. 284, 299-313 (2011) (developing procedures for new “post grant
review” and “inter partes review” proceedings). Thus, during this time period, patentees
concerned about the prospect of inter partes reexamination had an incentive to assert patents filed
before the November 1999 deadline. Greater fear of inter partes reexamination by NPEs than by
product-producing companies might introduce some bias into the analysis of my data. However,
the risk of bias appears low given the infrequency of inter partes reexaminations. Compare Inter
Partes Reexamination Filing Data—June 30, 2012, U.S. PATENT & TRADEMARK OFFICE ( June
2012), http://www.uspto.gov/patents/stats/IP_quarterly_report_June_30_2012.pdf (showing that,
since 2000, there have been 1659 total requests for inter partes reexamination), with LEX MACHINA, supra note 23 (showing that more than 37,000 total patent suits were filed in the United States
since 2000).
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above. Furthermore, recall that the United States is a party to the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS),182
which requires WTO member nations to offer a minimum of twenty years’
patent protection.183 Were the United States to formally reduce the patent
term without first renegotiating with the WTO, it could face trade sanctions from most of the industrialized world.184
A less drastic reform, and one that has the added benefit of not violating
the United States’ obligations under TRIPS, would be to increase the
frequency and magnitude of maintenance fee payments in the latter half of
the patent term. Today, patent owners are free from payment obligations
less than twelve years after issue, not long after the tide of patent litigation
shifts toward NPEs.185 Congress, or the PTO itself,186 could require additional annual fees for years nine through eleven and thirteen through
sixteen (or longer) and, moreover, could substantially increase the fee
required for each year.
This sort of reform could operate as something of a porous de facto term
reduction, bringing about the premature expiration of many patents that
would otherwise end up in the hands of patent acquisition firms,187 while at
the same time permitting product-producing companies that profit from
lucrative confidential licensing agreements to extend their patents up to
182
183
184

See supra note 85.
TRIPS Agreement, supra note 85, at 314.
TRIPS incorporates the dispute settlement provisions set forth in the General Agreement on Tarriffs and Trade. See General Agreement on Tarriffs and Trade, arts. XXII, XXIII,
Oct. 30, 1947, 55 U.N.T.S 187, 266; TRIPS Agreement, supra note 85, at 327. As a practical matter,
however, WTO member nations including the U.S. violate various aspects of the TRIPS
agreement quite often without ramification. See Colleen V. Chien, Tailoring the Patent System to
Work for Software and Technology Patents 1 (Nov. 15, 2012) (unpublished manuscript), available
at http://ssrn.com/abstract=2176520 (“The open secret among international law scholars is that
despite TRIPS’ broad pronoucnements, the treaty actually contains many flexibilities and
exceptions.”).
185 Under current law, maintenance fees are due at 3.5 years ($980), 7.5 years ($2480), and
11.5 years ($4110). 37 C.F.R. § 1.20(e)–(g) (2012). Patentees that qualify as “small entities” pay
only half this amount. Id. Those that qualify as “micro entities” pay one quarter. Leahy-Smith
America Invents Act, Pub. L. No. 112-29, § 10, 125 Stat. 284, 316-17 (2011) (to be codified at 35
U.S.C. § 41). The size, but not the timing, of these fees may change soon. See infra note 191.
186 The America Invents Act grants the PTO power to set its own fees “to recover the aggregate estimated costs to the Office for processing, activities, services, and materials relating to
patents.” Leahy-Smith America Invents Act § 10. As interpreted by the PTO, this provision gives
the agency “flexibility to set individual fees in a way that furthers key policy considerations.”
Setting and Adjusting Patent Fees, 77 Fed. Reg. 55,028 (proposed Sept. 6, 2012).
187 Under the current fee regime, approximately 50% of issued patents expire prematurely for
failure to make one of the three required payments. Dennis Crouch, Patent Maintenance Fees,
PATENTLYO (Sept. 26, 2012, 9:51 PM), http://www.patentlyo.com/patent/2012/09/patent-maintenancefees.html.
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twenty years from filing. Moreover, the rates at which patentees renewed
their patent rights late in the term would shed additional light on the
private value of aging patents—information that could help tailor a potential term reduction years down the road.188
Such a reform would be far from radical.189 By international and historical
standards, United States patent fees seem to have a considerable amount of
room to grow. Many countries, including the United Kingdom, Germany,
and Canada, already charge annual maintenance fees after the first few years
of patent life.190 Also, relative to GDP per capita, United States patent fees
this decade have been at or near an “all-time low”—about ten times cheaper
than they were in 1800.191
188 See Chien, supra note 24, at 305 (“The decision to maintain a patent signals its private
value to the patent owner.”). Other possible reforms exist that might mitigate the costs of lateterm patent enforcement. For example, the United States could implement a rule, loosely related
to the “working requirements” in effect in many other countries, that patent rights expire unless
they have been the subject of at least one bona fide license or good faith patent suit within a
certain number of years following issue. See Janice M. Mueller, The Tiger Awakens: The Tumultuous
Transformation of India’s Patent System and the Rise of Indian Pharmaceutical Innovation, 68 U. PITT.
L. REV. 491, 595 (2007) (“[S]everal advanced developing countries including India and Brazil have
retained domestic working requirements . . . .”). Alternatively, Congress or the courts could
institute a new defense akin to laches that denies relief to patentees who fail to quickly seek out
potential infringers and initiate licensing negotiations before filing suit. See Tun-Jen Chiang, The
Reciprocity of Search, 66 VAND. L. REV. 1, 50-58 (2013) (arguing that 35 U.S.C. § 287 should be
interpreted to “reallocate the search duty to patentees”).
189 Many commentators throughout the years have called for an increase in the size or frequency of patent maintenance fee payments. See Chien, supra note 179, at 361 (noting arguments in
favor of increasing maintenance fees that were voiced as early as the nineteenth century);
Francesca Cornelli & Mark Schankerman, Patent Renewals and R&D Incentives, 30 RAND J.
ECON. 197, 208 (1999) (finding that “renewal fees should rise much more with patent length than
existing fee schedules”); Magliocca, supra note 16, at 1836-37 (describing a “[d]ormancy
[t]ax . . . scheme in which [maintenance] fees are sharply increased and assessed more frequently”);
Kimberly A. Moore, Worthless Patents, 20 BERKELEY TECH. L.J. 1521, 1551-52 (2005) (recommending annual maintenance fee payments).
190 Renewing Your Patent, INTELL. PROP. OFFICE (U.K.), http://www.ipo.gov.uk/types/
patent/p-manage/p-renew.htm (last visited Mar. 15, 2013) (explaining that in the UK patents must
be renewed “on the 4th anniversary of the filing date and every year after that . . . up to 20
years”); GERMAN PATENT & TRADE MARK OFFICE, PCT APPLICANT’S GUIDE 5 (2012),
available at http://www.wipo.int/pct/guide/en/gdvol2/annexes/de.pdf (explaining that fees are
“payable for the third and each subsequent year following the international filing date”);
CANADIAN INTELLECTUAL PROP. OFFICE, MANUAL OF PATENT OFFICE PRACTICE § 24.02.01
(last updated 2010), available at http://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/vwapj/
rpbb-mopop-eng.pdf (“In order to maintain a patent application in effect, an applicant must pay
maintenance fees for each one-year period from the second anniversary of the filing date of the
application.”).
191 Gaétan de Rassenfosse & Bruno van Pottelsberghe, The Role of Fees in Patent Systems:
Theory and Evidence 6 (Intellectual Prop. Research Inst. of Austl., Working Paper No. 7/10, 2010),
available at http://www.ipria.org/publications/wp/2010/Working%20Paper%207_2010.pdf. Recently
proposed changes to the maintenance fee schedule would increase (for small and large entities) the
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CONCLUSION
Whatever the precise mechanism employed, the results presented in this
Article suggest that society might be better off if patent rights diminished
earlier than they do under current law. In a world in which at least some
products are out of date by the time they hit store shelves, the last few years
of a two decade–long patent term seem unlikely to incentivize greater
innovation. To the contrary, it appears that the waning years of patent
protection primarily benefit litigation-oriented patentees who do little more
with their aging patent rights than impose steep legal costs on those selling
successful products. Perhaps through future research that dispels concerns
raised by the limitations discussed above, we will soon gain a deeper
understanding of the practical costs and benefits of the final years of the
patent term that will spur legislative action to trim the nation’s everincreasing thicket of aging patents.

first fee by 42%, the second by 26%, and the third by 56%. See Setting and Adjusting Patent Fees,
77 Fed. Reg. 55,028, 55,040 tbl.4 (proposed Sept. 6, 2012) (displaying the current and proposed
fee structure).

